amerihealth
Advanced Search

Bioengineered Skin Substitutes
MA11.015ah

Policy

​This policy uses coverage criteria primarily based on applicable Medicare statutes, regulations, NCDs, LCDs, CMS manuals and other applicable Medicare coverage documents. In the absence of fully established coverage criteria from these Medicare coverage documents for a specific medical service or item, the criterion/indication/service indicated by an asterisk below (*) is based on internal coverage criteria developed by the Company in consideration of peer-reviewed medical literature, clinical practice guidelines, regulatory status, and/or expert opinion.

The scope of this policy includes the use of bioengineered skin substitutes for the treatment of lower extremity skin ulcers, second- and third-degree burns, acute wounds, post-Mohs, and post-surgical use​. The use of bioengineered skin substitutes for all other wounds is not discussed, and is beyond the scope of this policy. For the use of bioengineered skin substitutes for reconstructive breast surgery, see policy MA11.030.

LOWER EXTREMITY CHRONIC NON-HEALING WOUNDS

MEDICALLY NECESSARY FOR LOWER EXTREMITY CHRONIC NON-HEALING WOUNDS

Lower extremity chronic non-healing wounds

The use of bioengineered skin substitutes, and their applications, in the treatment of lower extremity chronic non-healing wounds with a failed response*, is considered medically necessary and, therefore covered, when ALL the following are met:  
  • The wound has a skin deficit at least 1.0 cm2​ in size​
  • Partial- or full-thickness ulcers do not involve tendon, muscle, joint capsule or exhibit exposed bone or sinus tracts, and have a clean granular base
  • The wound is clean and free of infection, necrotic debris, or exudate, and without evidence of underlying osteomyelitis
  • The wound has adequate circulation/oxygenation to support tissue growth/wound healing as evidenced by physical examination (e.g., Ankle-Brachial Index [ABI] no less than 0.60, toe pressure > 30 mm Hg)
  • The requested bioengineered skin substitute is listed below in the applicable wound indication AND the criteria for that indication are met
  • ONE of the following is met:
    • Presence of a full-thickness skin loss ulcer that is the result of abscess, injury, or trauma that has failed to respond* to appropriate control of infection, foreign body, tumor resection, or other disease process for a period of 4 weeks or longer
    • For diabetic lower extremity ulcers: 
      • The individual’s medical record reflects a diagnosis of type 1 or type 2 diabetes and also reflects medical management for this condition
      • Presence of neuropathic diabetic foot ulcer(s) having failed to respond* to documented conservative wound-care measures of greater than 4 weeks, during which the individual is compliant with recommendations, and without evidence of underlying osteomyelitis or nidus of infection
    • For venous leg ulcers (VLU):
      • Presence of a venous stasis ulcer for at least 3 months but unresponsive*​ to appropriate wound care for at least 30 days with documented compliance​
*Note: A failed response is defined as an ulcer or skin deficit that has failed to respond to documented appropriate wound-care measures, has increased in size or depth, or has not changed in baseline size or depth and has no indication that improvement is likely (such as granulation, epithelialization, or progress towards closing). ​

NOT MEDICALLY NECESSARY FOR LOWER EXTREMITY CHRONIC NON-HEALING WOUNDS

When the associated medical necessity criteria above are not met, the use of bioengineered skin substitutes, and their application, are considered not medically necessary.​

EXPERIMENTAL/INVESTIGATIONAL FOR LOWER EXTREMITY CHRONIC NON-HEALING WOUNDS

The use of bioengineered skin substitutes, and their application, for indications not approved by the US Food and Drug Administration (FDA) or in accordance with the manufacturer's package insert instructions/guidelines are considered experimental/investigational and, therefore, not covered because the safety and/or effectiveness of this product cannot be established by review of the available published peer-reviewed literature.

All other uses of bioengineered skin substitutes (such as, but not limited to, acute wounds, post-Mohs, post-surgical use), and their applications, are considered experimental/investigational and, therefore, not covered because the safety and/or effectiveness of these products cannot be established by review of the available published peer-reviewed literature.

Refer to Attachment A for a list of ​skin substitutes, which are represented by a specific HCPCS code, and their approved indications. This list does not include all FDA-approved/regulated skin substitutes.

DEEP SECOND-DEGREE (PARTIAL-THICKNESS) BURNS AND THIRD-DEGREE (FULL-THICKNESS) BURNS​

MEDICALLY NECESSARY FOR DEEP SECOND-DEGREE (PARTIAL-THICKNESS) BURNS AND THIRD-DEGREE (FULL-THICKNESS) BURNS

Biobrane/Biobrane Glove
​
The use of Biobrane/Biobrane Glove, and its application,​ is considered medically necessary and, therefore, covered for the treatment of deep second-degree (partial-thickness) burn wounds when ALL of the following medical necessity criteria are met​* (FDA):​
  • The treatment is specific to noninfected partial-thickness burn wounds and donor site wounds* (American Burn Association, 2025; FDA)
  • Initial excision of the burn wound is complete (i.e., eschar and nonviable tissue are removed)* (American Burn Association, 2025)
  • Hemostasis is achieved* (American Burn Association, 2025)
  • Sufficient autograft tissue is not available at the time of excision (e.g., inadequate amounts of donor autograft tissue available)* (American Burn Association, 2025)
  • Autograft is not desirable due to the individual's physiologic condition (e.g., individual has multisystem injuries such that creating new wounds may cause undue stress)* (American Burn Association, 2025)
Epicel

The use of Epicel, and its application, is considered medically necessary and, therefore, covered for the treatment of deep dermal or full-thickness burns when ALL of the following criteria are met* (FDA)
  • The burns comprise 30 percent or greater of total body surface area (FDA)
  • When used in conjunction with split-thickness autografts or alone in individuals for whom split-thickness autografts may not be an option due to the severity and extent of their burns (FDA)
  • When provided in accordance with the humanitarian device exemption (HDE) specifications of the FDA* 
Note: Bioengineered skin substitutes are considered to be devices by the FDA. Some bioengineered skin substitutes (e.g., Epicel) are approved by the FDA through an HDE approval. An HDE may only be used in facilities that have an institutional review board (IRB) to oversee the clinical application of such devices. The IRB must approve the application of the device to ensure that it will be used in accordance with the FDA-approved indication. In addition, documentation of IRB approval may be requested by the Company to ensure compliance with the HDE indication* (FDA, HDE postmarket activities).
​
Integra Bilayer Matrix Wound Dressing (BMWD), Integra Dermal Regeneration Template, and Integra Meshed Bilayer Wound Matrix 

The use of Integra Bilayer Matrix Wound Dressing, Integra Dermal Regeneration Template, and Integra Meshed Bilayer Wound Matrix, and their application,​ are considered medically necessary and, therefore, covered for the treatment of second- and third-degree burn wounds when ALL of the following medical necessity criteria are met* (FDA):​
  • The treatment is specific to noninfected deep partial- and full-thickness burn wounds* (American Burn Association, 2025; FDA)
  • Initial excision of the burn wound is complete (i.e., eschar and nonviable tissue are removed)* (American Burn Association, 2025; FDA)
  • Integra Dermal Regeneration Template must be applied on the same day as the initial excision of the recipient site* (FDA)
  • Hemostasis is achieved* (American Burn Association, 2025)
  • Sufficient autograft tissue is not available at the time of excision (e.g., donor autograft tissue is thin and frail)* (American Burn Association, 2025; FDA)
  • Autograft is not desirable due to the individual's physiologic condition (e.g., individual has multisystem injuries such that creating new wounds may cause undue stress)* (American Burn Association, 2025; FDA)​
OrCel
​
The use of OrCel (bilayered cellular matrix), and its application,​ is considered medically necessary and, therefore, covered for the treatment of fresh, clean split-thickness donor site wounds in individuals with second- and third-degree burns* (FDA)

TransCyte 
​
The use of TransCyte, and its application, is considered medically necessary and, therefore, covered for the treatment of second- and third-degree burn wounds when ALL of the following medical necessity criteria are met* (FDA):​
  • ​The treatment is specific to a temporary wound covering of ONE of the following* (FDA): 
    • Noninfected deep partial-thickness and full-thickness burn wounds prior to autograft placement* (FDA)
    • Noninfected mid-dermal to indeterminate depth burn wounds that may be expected to heal without autografting* (FDA)
  • Initial excision of the burn wound is complete (i.e., eschar and nonviable tissue is removed)* (American Burn Association, 2025)
  • Hemostasis is achieved* (American Burn Association, 2025)
EXPERIMENTAL/INVESTIGATIONAL FOR DEEP SECOND-DEGREE (PARTIAL-THICKNESS) BURNS AND THIRD-DEGREE (FULL-THICKNESS) BURNS

The use of any bioengineered skin substitute NOT listed above, and its application, in the treatment of deep second-degree (partial-thickness) burns and third-degree (full-thickness) burns, is considered experimental/investigational and, therefore, not covered because the safety and efficacy of the products cannot be established by review of the available published peer-reviewed literature.

All other uses of the bioengineered skin substitutes listed above (such as, but not limited to, acute wounds, post-Mohs, post-surgical use), and their applications, are considered experimental/investigational and, therefore, not covered because the safety and/or effectiveness of these products cannot be established by review of the available published peer-reviewed literature.

The use of the following product(s), and their application, are considered experimental/investigational for the treatment of burns and, therefore, are not covered because the safety and/or effectiveness of these product(s) cannot be established by review of the available published peer-reviewed literature (this list may not be all inclusive):
  • Permeaderm glove
ADDITIONAL COVERAGE LIMITATIONS FOR ALL ABOVE USES

  • ​​FDA labeling for most skin substitutes include language suggesting multiple applications; however, it is not expected that every wound in every individual will require the maximum number of applications listed on the product label​
  • It is expec​​ted that a specific skin substitute will be used for each documented wound, and in compliance with FDA assessments and guidelines for the specific skin substitute
  • ​Partial thickness loss with the retention of epithelial appendages is not a candidate for grafting or replacement, as epithelium will repopulate the deficit from the appendages, negating the benefit of overgrafting
  • Skin substitutes will be allowed for the episode of wound care in compliance with FDA guidelines for the specific product not to exceed 10 applications or treatments. In situations where more than one specific product is used, it is expected that the number of applications or treatments will still not exceed 10​
  • ​​Simultaneous use of more than one skin substitute for the treatment of a single wound within a 12-week period of time is considered not medically necessary. A change in skin substitute within the 12-week treatment period is covered, as long as the 10-application limit per wound is not exceeded​
  • Repeat or alternative applications of skin substitutes are considered not medically necessary when a previous full course of applications was unsuccessful. Unsuccessful treatment is defined as an increase in size or depth of an ulcer or no change in baseline size or depth, and no sign of improvement or indication that improvement is likely (such as granulation, epithelialization or progress towards closing) for a period of 4 weeks past start of therapy
  • Retreatment of healed ulcers, those showing greater than 75 percent size reduction and smaller than 0.5 square cm, is considered not medically necessary
  • Skin substitutes are contraindicated and considered not medically necessary in individuals with inadequate control of underlying conditions or exacerbating factors (e.g., uncontrolled diabetes, active infection, and active Charcot arthropathy of the ulcer extremity, vasculitis, or continued tobacco smoking without professional provider attempt to effect smoking cessation)
  • ​​Skin substitutes are contraindicated in individuals with known hypersensitivity to any component of the specific skin substitute (e.g., allergy to avian, bovine, porcine, equine products)
  • Repeat use of surgical preparation services in conjunction with skin substitute application codes will be considered not medically necessary. It is expected that each wound will require the use of appropriate wound preparation code at least once at initiation of care prior to placement of the skin substitute
  • Re-treatment within 1 year of any given course of skin substitute treatment for a venous stasis ulcer or (diabetic) neuropathic foot ulcer is considered treatment failure and does not meet medically necessary criteria for re-treatment of that ulcer with a skin substitute procedure​
REQUIRED DOCUMENTATION ​FOR ALL ABOVE USES

The individual's medical record must reflect the medical necessity for the care provided. These medical records may include, but are not limited to: records from the health care professional's office, hospital, nursing home, home health agencies, therapies, and test reports.

The Company may conduct reviews and audits of services to our members, regardless of the participation status of the provider. All documentation is to be available to the Company upon request. Failure to produce the requested information may result in a denial for the service.

Documentation (in the pre-service record) specifically addressing circumstances as to why the wound has failed to respond to standard wound care treatment of greater than 4 weeks and must reference specific interventions that have failed. Such record should include updated medication history, review of pertinent medical problems that may have occurred since the previous wound evaluation, and explanation of the planned skin replacement surgery with choice of skin substitute product. The procedure risks and complications should also be reviewed and documented. Documentation of smoking cessation counseling and cessation measures prescribed, if applicable, must also be documented in the individual's record.

In all wound management the ulcer must be free of infection and underlying osteomyelitis with documentation of the conditions that have been treated and resolved prior to the institution of skin substitute therapy.​

Documentation of response requires measurements of the initial wound, measurements at the completion of at least 4 weeks of appropriate wound care, and measurements immediately prior to placement and with each subsequent placement of the skin substitute.​

Prior to the application of the skin substitute for diabetic or venous insufficiency ulcers, it is expected that the medical record documentation will contain evidence of the following:
  • Documentation that conservative measures have failed
  • Documentation that the ulcer has failed to decrease in size and depth, or that there has been no change in baseline size or depth with no sign of improvement, or no indication that improvement is likely​
For the skin substitute for diabetic or venous insufficiency ulcers, it is expected that the medical record documentation will contain evidence of the following:
  • The individual's medical record must reflect the frequency of skin substitute application, and this should be consistent with each individual's history and response to the skin substitute application and product safety criteria. Repeated application to the same wound within the same treatment period without signs of improvement may be denied
  • Documentation that the skin substitute product was appropriately applied​
BILLING REQUIREMENTS

​​​Application codes are not to be reported for application of non-graft wound dressings (e.g., gel, ointment, foam, liquid, or injected substances) or for a biologic implant for soft tissue reinforcement. Such products are considered part of other standard management procedures, if medically necessary, and not separately payable.

Guidelines

This policy is consistent with Medicare’s coverage determination for skin substitutes. The Company's payment methodology may differ from Medicare.

Chronic wounds are defined as wounds that do not respond to standard wound therapy for at least a 30-day period during organized comprehensive conservative therapy.

A non-healing wound (i.e., a "failed response") is defined as an ulcer or skin deficit that has failed to respond to documented appropriate wound-care measures, has increased in size or depth, or has not changed in baseline size or depth and has no indication that improvement is likely (such as granulation, epithelialization, or progress towards closing).​​​

Appropriate wound therapy includes, but is not limited to:​
  • Control of edema, venous hypertension or lymphedema
  • Control of any nidus of infection or colonization with bacterial or fungal elements
  • Elimination of underlying cellulitis, osteomyelitis, foreign body or malignant process
  • Appropriate debridement of necrotic tissue or foreign body (exposed bone or tendon)
  • For diabetic foot ulcers, appropriate non-weight bearing or off-loading pressure​
  • For venous stasis ulcers, compression therapy provided with documented diligent use of multilayer dressings, compression stockings of > 20 mm Hg pressure, or pneumatic compression​
  • Provision of wound environment to promote healing (protection from trauma and contaminants, elimination of inciting or aggravating processes)
BENEFIT APPLICATION

Subject to the terms and conditions of the applicable Evidence of Coverage, skin substitutes with US Food and Drug Administration (FDA) clearance/approval for use in the treatment of burns and chronic non-healing wounds are covered under the medical benefits of the Company’s Medicare Advantage products when the medical necessity criteria listed in the medical policy are met.

Subject to the terms and conditions of the applicable Evidence of Coverage, skin substitutes that do not meet the medical necessity criteria listed in the medical policy, including, but not limited to, Epicel, are not eligible for payment under the medical benefits of the Company’s Medicare Advantage products because they are considered experimental/investigational and, therefore, not covered.

Services that are experimental/investigational are excluded for the Company’s Medicare Advantage products. Therefore, they are not eligible for reimbursement consideration.

US FOOD AND DRUG ADMINISTRATION STATUS

There are numerous skin substitute products approved by the FDA for wound care.

Description

SKIN LAYERS

Skin is composed of two layers: the epidermis and the dermis. The outermost layer is called the epidermis, and immediately beneath the epidermis is the dermis. These layers are separated by a basement membrane, which helps stabilize the epidermis to the dermis. Because the epidermis contains no blood vessels, the underlying dermis is the supplier of nutrients to the skin. The dermis consists of a superficial papillary layer of loose connective tissue that contains capillaries, elastic fibers, reticular fibers, and some collagen. A deeper reticular layer of the dermis consists of dense connective tissue that contains larger blood vessels, interlaced elastic fibers, coarse branching collagen fibers, fibroblasts, mast cells, nerve endings, lymphatics, hair follicles, and sebaceous and sweat glands.

There are currently a wide variety of products available for soft tissue coverage to affect closure. These products may be derived from allogeneic, xenogeneic, synthetic sources or a combination of any or all of these types of materials. However, without the component of the recipient’s own distinct epithelium and cellular skin elements, permanent skin replacement or coverage by the graft cannot be accomplished.

SKIN GRAFTS

Historically, skin grafts have been employed to cover a skin deficit or replace lost tissue. Autologous skin grafts, also referred to as autografts, are permanent covers that use skin from different parts of the individual's body. These grafts consist of the epidermis and a dermal component of variable thickness. A split-thickness skin graft includes the entire epidermis and a portion of the dermis. A full-thickness skin graft removes all the layers of the skin. Although autologous skin grafts are the optimum choice for wound coverage, areas of skin for harvesting may be limited, particularly in cases of large burns; in addition, the procedures are invasive and painful. Allografts (which use skin from another human [e.g., a cadaver]) and xenografts (which use skin from another species [e.g., porcine or bovine]) may also be employed as temporary skin replacements, but they must later be covered by an autograft or the ingrowth of the individual's own skin.

SKIN SUBSTITUTES

Because of problems inherent with autografts, allografts, and xenografts, skin substitutes were developed. Skin substitutes (also referred to as tissue-engineered skin substitutes, human skin equivalents, or skin alternatives) are products that contain cells such as fibroblasts and keratinocytes in scaffolds of natural or synthetic matrices. The matrices provide a framework for mechanical stability and tissue infiltration. Cellular elements are predominantly derived from epidermal components, dermal components, or both in a composite graft. Skin substitutes are manufactured under a variety of trade names and marketed for various purposes.

Skin substitutes are classified into the following types:
  • Human skin allografts: derived from donated human skin (cadavers) that has been processed to remove the cellular components and retain the structural proteins of the dermis, and to avoid immunologic rejection. They are available in different forms to allow scaffolding, soft tissue filling, growth factors, and other bioavailable hormonal or enzymatic activity.
  • Allogeneic matrices: derived from human neonatal fibroblasts of the foreskin that may contain metabolically active or regenerative components primarily used for soft tissue support, though some have been approved for the treatment of full-thickness skin and soft tissue loss. Most are biodegradable and disappear after 3 to 4 weeks of implantation.
  • Composite matrices: derived from human keratinocytes and fibroblasts supported by a scaffold of synthetic mesh or xenogeneic collagen. These are also referred to as human skin equivalent but are unable to be used as autografts due to immunologic rejection or degradation of the living components by the host. Active cellular components continue to generate bioactive compounds and protein that may accelerate wound healing and epithelial regrowth.
  • Acellular matrices: derived from sources other than human skin and include the majority of skin substitutes. All are composed of allogeneic (i.e., from another human) or xenogeneic (i.e., from nonhuman species, such as bovine and porcine) derived collagen, membrane, or cellular remnants proposed to simulate or exaggerate the characteristics of human skin. All are proposed to promote healing by the creation of localized intensification of an array of hormonal and enzymatic activity to accelerate closure by migration of native dermal and epithelial components, rather than function as distinctly incorporated tissue closing the skin defect.
Although the precise mechanism by which these products enhance wound repair is not understood, it is thought that maintenance of a biochemically balanced moist wound environment, the structural support for tissue regeneration, and/or the application of cytokines and growth factors to the wound bed may contribute to the healing process. Skin substitutes were originally designed to cover acute extensive burns in individuals with insufficient autologous skin for grafting. However, the use of skin substitutes has since been expanded to include treatment of many other types of wounds.

REGULATION OF SKIN SUBSTITUTES

Based on the skin substitute's composition and origin, the US Food and Drug Administration (FDA) regulates skin substitutes under one of the following categories:
  • Human- and human/animal-derived products regulated through the premarket approval (PMA) process
  • Animal-derived products and synthetic products regulated through the 510(k) process
  • Human-derived products regulated as human cells, tissue, and cellular and tissue-based products (HCT/Ps)
  • Human- and human/animal-derived products regulated as a humanitarian use device (HUD) obtained through a humanitarian device exemption (HDE)
FDA PREMARKET APPROVAL 
PMA is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices. Class III devices are those that support or sustain human life, are of substantial importance in preventing impairment of human health, or that present a potential, unreasonable risk of illness or injury. Because of the level of risk associated with Class III devices, the FDA has determined that general and special controls alone are insufficient to ensure the safety and effectiveness of Class III devices. Therefore, these devices require a PMA application in order to obtain marketing clearance.

PMA is the most stringent type of device marketing application required by the FDA. The applicant must receive FDA approval of its PMA application prior to marketing the device. PMA approval is based on a determination by the FDA that there is sufficient valid scientific evidence to ensure that the device is safe and effective for its intended use(s).

FDA PREMARKETING NOTIFICATION (510[K])
A Premarketing Notification (510[k]) is a process in which applicants must demonstrate that the device to be marketed (i.e., a Class II device) is "substantially equivalent" to a pre-existing legally marketed device (predicate) in terms of safety and effectiveness. The predicate must have been approved either via PMA or 510(k). This process is usually used when manufacturers make small changes to a previously approved device that are thought to improve effectiveness without compromising safety, thus allowing for expedited approval without costly and lengthy scientific studies confirming safety and effectiveness.

HUMAN CELLS, TISSUES, AND CELLULAR AND TISSUE-BASED PRODUCTS
Cells and tissues taken from human donors and transplanted to a recipient are regulated under Public Health Services (PHS) 361 [21 Code of Federal Regulations (CFR) 1270 and 1271]. This regulation describes the rules concerning the use of human cells, tissues, and HCT/Ps for human medical purposes. The final rule, 21 CFR Part 1271, became effective on April 4, 2001, for human tissues intended for transplantation that are regulated under section 361 of the PHS Act and 21 CFR Part 1270. HCT/Ps are regulated by the Center for Biologics Evaluation and Research (CBER). CBER is responsible for regulating biological and related products including blood, vaccines, allergenics, tissues, and cellular and gene therapies. Establishments producing HCT/Ps must register with the FDA and list their HCT/Ps. HCT/Ps establishments are not required to demonstrate the safety or effectiveness of their products and the FDA does not evaluate the safety or effectiveness of these products.

HUMANITARIAN DEVICE EXEMPTION
In rare instances, certain medical devices intended to be used for humanitarian purposes are evaluated by the FDA through the HDE process. A device approved in this manner is designated as a HUD. A HUD designation permits the use of certain medical devices when there is no comparable device available to treat or diagnose a disease or condition affecting fewer than 4000 individuals annually. Because clinical investigation demonstrating the device's efficacy is not feasible (given the low prevalence of the disease in the population), an HDE grants manufacturers an exemption to the usual PMA process and allows marketing of the device only for the FDA-labeled HDE indication(s).

Under FDA requirements, a HUD may only be used after institutional review board (IRB) approval has been obtained for the use of the device in accordance with the FDA-labeled indication(s) under the HDE.

COMMON TYPES OF WOUNDS

BURNS
Burns are major threats that can lead to extensive tissue and fluid loss; they also provide openings for systemic infection. Burn severity is rated based on damage to skin layers. Superficial or first-degree burns involve only the outer layer of skin, the epidermis, and typically heal in 3 to 5 days. Partial-thickness or second-degree burns can be classified as superficial or deep. Superficial second-degree burns involve the entire epidermis and upper layers of the dermis, and should heal in 5 to 21 days without grafting. Deep second-degree burns involve the destruction of the entire epidermis and most of the dermis, and can quickly evolve into a full-thickness (or third-degree) burn. Deep second-degree burns will most likely need excision and skin grafting to heal. Full-thickness or third-degree burns involve the destruction of all layers of the skin, and often injure underlying subcutaneous adipose tissue as well. Conventional treatment for major burns consists of early staged surgical wound excision, in which eschar is removed and a granulating wound is exposed to serve as a bed for subsequent grafting and wound closure. Early burn wound excision has been shown to improve survival, decrease infection rates, decrease the formation of hypertrophic scars, and decrease the length of hospital stay.

DIABETIC FOOT ULCERATIONS
Diabetic foot ulcerations are common and occur in individuals who have type I or type II diabetes. The current standard of care (SOC) for diabetic ulcers includes removal of mechanical stress (e.g., non-weight-bearing regimen), sharp debridement when necessary, and wound care (e.g., saline-moistened dressings); however, because only 24 percent of these ulcers heal after 12 weeks of treatment, these regimens are not considered particularly effective.

VENOUS ULCERATIONS
Venous ulcerations are a result of a pathophysiologic process in the maintenance of tissue integrity. The standard therapy for venous ulcers is compression. Healing after initiation of compression therapy is predictive of long-term results. Ulcers that are not reduced by greater than 40 percent within 3 weeks of treatment are unlikely to heal and may require complex care.

EPIDERMOLYSIS BULLOSA/RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Epidermolysis bullosa is a family of genetic disorders that cause the skin to be very fragile and to blister easily after minor injury or friction, such as rubbing or scratching. The disease may occur in a relatively mild form, but it may also be disabling and sometimes fatal. Dystrophic epidermolysis bullosa (DEB) is one of the major forms of epidermolysis bullosa. DEB can be classified into three major types based on severity:
  • Autosomal recessive dystrophic epidermolysis bullosa, Hallopeau-Siemens type (RDEB-HS): the most severe form of the condition (blisters are present over the whole body and affect mucous membranes; leads to severe scarring)
  • Autosomal recessive dystrophic epidermolysis bullosa, non-Hallopeau-Siemens type (non-HS RDEB): less severe than RDEB-HS (blisters are limited to the hands, feet, knees, and elbows, but may be widespread in more severe cases; scarring is limited to areas where blisters have occurred and are not as severe as in RDEB-HS)
  • Autosomal dominant type (DDEB): milder than the autosomal recessive forms (blisters limited to the hands, feet, knees, and elbows; blisters heal with scarring, but it is less severe).
Recessive dystrophic epidermolysis bullosa wounds have been treated with skin substitutes, one of which (OrCel) has been approved by the FDA under the HDE.

OTHER TYPES OF WOUNDS
Other wounds include, but are not limited to, partial- and full-thickness wounds, pressure ulcers, chronic vascular ulcers, surgical wounds (e.g., donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (e.g., abrasions, lacerations, skin tears), and draining wounds.​

PEER-REVIEWED LITERATURE

Bioengineered skin substitutes or cellular and tissue-based products (CTPs), referred to as skin substitutes by Centers for Medicare & Medicaid (CMS), the Current Procedural Terminology (CPT), and the Healthcare Common Procedure Coding manuals, have been developed to circumvent problems inherent with autografts, allografts, and xenografts. They are biologic covers for refractory wounds with full-thickness skin loss secondary to third-degree burns or other disease processes such as diabetic neuropathic ulcers and the skin loss of chronic venous stasis or venous hypertension. The production of these products generally involves the creation of immunologically inert biologic products containing protein, hormones or enzymes seeded into a matrix that may provide protein or growth factors proposed to stimulate or facilitate healing or promote epithelialization. A variety of biosynthetic and tissue-engineered skin substitution products marketed as human skin equivalents (HSE) or cellular or tissue-based products (CTP) are manufactured under an array of trade names and marketed for a variety of indications. All are procured, produced, manufactured, processed and promoted in sufficiently different manners to preclude direct product comparison for equivalency or superiority in randomized controlled trials (RCTs). Sufficient data are available to establish distinct inferiority to human skin autografts and preclude their designation as skin equivalence.

Bioengineered skin substitutes or CTPs are classified into the following types:
  • Human skin allografts derived from donated human skin (cadavers)
  • Allogeneic matrices derived from human tissue (fibroblasts or membrane)
  • Composite matrices derived from human keratinocytes, fibroblasts, and xenogeneic collagen
  • Acellular matrices derived from xenogeneic collagen or tissue
  • Human skin allografts bioengineered from human skin components and human tissue that have had intact cells removed or treated to avoid immunologic rejection. They are available in different forms, promoted to allow scaffolding, soft tissue filling, growth factors, and other bioavailable hormonal or enzymatic activity.
  • Allogeneic matrices are usually derived from human neonatal fibroblasts of the foreskin that may contain metabolically active or regenerative components primarily used for soft tissue support, although some have been approved for the treatment of full-thickness skin and soft tissue loss. Most are biodegradable and disappear 3 to 4 weeks after implantation.
  • Composite matrices are derived from human keratinocytes and fibroblasts supported by a scaffold of synthetic mesh or xenogeneic collagen. These are also referred to as xenogeneic human skin equivalent but are unable to elude an autograft due to immunologic rejection or degradation of the living components by the host. Active cellular components continue to generate bioactive compounds and protein that may accelerate wound healing and epithelial regrowth.
  • Acellular matrices are derived from other than human skin and include the majority of bioengineered skin substitutes. All are composed of allogeneic- or xenogeneic-derived collagen, membrane, or cellular remnants proposed to stimulate or exaggerate the characteristics of human skin. All propose to promote healing by the creation of localized intensification of an array of hormonal and enzymatic activity to accelerate closure by migration of native dermal and epithelial components, rather than function as distinctly incorporated tissue closing the skin defect.
Sui et al. (2024) conducted a systematic review of 15 RCTs to evaluate the effectiveness and safety of the application of dermal matrix therapy as an adjuvant treatment to SOC. Diabetic foot ulcers (DFUs) can lead to diabetic foot infection, lower leg amputation, and even death. Although SOC practices have been known as the gold standard for DFU care, SOC alone may not be enough to heal all DFUs and prevent recurrence. This study included 1524 individuals. Of them, 689 were treated with SOC alone, while 835 received SOC plus dermal matrix. Compared with the SOC group, a significantly shorter time (mean difference [MD], 2.84; 95 percent confidence interval [CI], 1.37–4.32; P<0.001) was required to achieve complete healing in the dermal matrix group. A significantly higher complete healing rate (odds ratio [OR], 0.40; 95 percent CI, 0.33–0.49; P<0.001) and lower overall (risk ratio [RR], 1.83; 95 percent CI, 1.15–2.93; P=0.011) and major (RR, 2.64; 95 percent CI, 1.30–5.36; P=​0.007)] amputation risks were achieved in the dermal matrix group compared with the SOC group. No significant difference in the wound area, ulcer recurrence rate, and complication risk between the two groups was observed. Study limitations are that (1) a small sample size was included; (2) products among the manufacturers varied, which may have resulted in bias; (3) the trials were not blinded; (4) there was a lack of concealment to the investigator; and (5) follow-up times varied. The authors concluded that dermal matrix used as an adjuvant therapy in conjunction with SOC effectively improved the healing process of DFUs and reduced the amputation risk compared with SOC alone. This use of dermal matrix was also well tolerated by the individuals, with no additional risk of complications (Cazzell et al., 2017, 2019b, and Zelen et al., 2016, are included in this study.)

Alomairi et al. (2024) conducted a systematic review and meta-analysis to assess the application and effectiveness of human amniotic membrane (HAM) in the treatment of diabetic and venous leg ulcers to improve the management of chronic wounds. This review included 10 RCTs involving 633 individuals who were randomly assigned to either a treatment group receiving amniotic membrane (n=323) or a control group receiving SOC (n=310). HAM was used in all studies rather than synthetic types. Diabetes was the primary cause of the ulcer. The ulcers had a mean size of 4.3 cm2 in the standard care group and 3.6 cm2 in the amniotic membrane group. Findings revealed that HAM treatment significantly accelerated ulcer closure, with over 90 percent complete healing compared with standard care. The authors noted that several complications occurred during treatment. The follow-up was limited to 12 to 16 weeks, proving only short-term efficacy and exposing possible complications from the treatment itself. Study limitations include a limited number of RCTs, small sample sizes in some studies, and large population of older male individuals, which may have affected healing times. In addition, no standardized protocol for HAM preparation was followed, which possibly affected product quality. Many of the studies focused on individuals with diabetes with leg ulcers. Also, short-term follow-up across trials varied between 6 and 16 weeks, emphasizing the need to evaluate the long-term efficacy and safety of HAM. Additional research is needed, particularly focusing on a diverse array of cutaneous ulcers, given that most of the studies primarily addressed diabetic ulcers and often had small sample sizes (Serena et al., 2022, Serena et al., 2020, Snyder et al., 2016, Bianchi et al., 2018, DiDomenico et al., 2016, Lavery et al., 2014, Zelen et al., 2014, Tettelbach et al., 2019, Zelen et al., 2013, and Zelen et al., 2016, are all included in this review.)

A Hayes Health Technology Assessment for Skin Substitutes for Venous Leg Ulcers in Adults concluded that a low-quality body of evidence provided consistent evidence suggesting that acellular and cellular skin substitutes may improve healing of chronic venous leg ulcers when used in conjunction with standard wound care (SWC). The Hayes report gives a “C” rating for the use of acellular or cellular skin substitutes as an adjunct to SWC to treat adults with chronic, uninfected venous leg ulcers that have not healed with SWC alone. Evidence directly comparing different cellular skin substitutes with SWC alone and for skin substitute products or types is extremely limited and of very low quality. Skin substitutes appear to be safe, and no major safety concerns were reported. Additional large, well-designed clinical trials are needed to better evaluate the comparative effectiveness and safety of skin substitutes as adjuncts to SWC and as alternatives to other skin substitutes. The skin substitutes that were a part of the evidence base for this report included EPIFIX, TheraSkin, Talymed, and PriMatrix (Hayes, Skin Substitutes for Venous Leg Ulcers in Adults, 2020; updated 2023).

A Hayes report (2020; updated 2023) for acellular skin substitutes for chronic foot ulcers in adults with diabetes indicates that there is an overall low-quality body of evidence suggesting that acellular skin substitutes appear to heal more chronic DFUs than SWC alone and in a shorter period. While acellular skin substitutes appear to have some benefits over cellular skin substitutes, in terms of the incidence, time to healing, and possibly quality of life (QOL), no definitive conclusions can be drawn regarding comparative effectiveness and safety of these products due to the limited number of studies overall; this also includes the individual skin substitutes. Questions remain about the effect of acellular skin substitutes on the incidence of amputation and ulcer recurrence due to the limited number of studies on these outcomes. Evidence that directly compares different acellular skin substitutes or compares acellular with cellular skin substitutes is extremely limited and of very low quality, resulting in an inability determine whether any one product or product type is superior. The acellular skin substitutes that were part of the evidence base for this report include EPIFIX, EPICORD, AmnioBand, AmnioExcel, MatriStem MicroMatrix, and DermACELL (Hayes, Acellular Skin Substitutes for Chronic Foot Ulcers in Adults with Diabetes Mellitus, 2020; updated 2023).

A Hayes report (2020; updated 2023) for Cellular Skin Substitutes for Chronic Foot Ulcers in Adults with Diabetes indicates that there is an overall low-quality body of evidence that assesses the comparative effectiveness and safety of cellular skin substitutes incremental to SWC alone for the treatment of DFUs in individuals with diabetes. The overall quality of the bodies of evidence comparing cellular skin substitutes with other cellular skin substitutes and cellular skin substitutes with acellular skin substitutes as adjuncts to SWC are very low. Although cellular skin substitutes appear to benefit DFU healing over SWC alone, evidence on individual products to assess whether any cellular skin substitute is more effective than the others is insufficient. Large, well-designed clinical trials are needed to better evaluate the comparative effectiveness and safety of cellular skin substitutes as adjuncts to SWC and as alternatives to acellular skin substitutes. The cellular skin substitutes that were a part of the evidence base for this report include Affinity, GRAFIX, Matristem MicroMatrix, and TheraSkin (Hayes, Cellular Skin Substitutes for Chronic Foot Ulcers in Adults with Diabetes Mellitus, 2020; updated 2023).

In a technical brief prepared for the Agency for Healthcare Research and Quality (AHRQ), Snyder et al. (2020) evaluated skin substitutes for treating chronic wounds. Systematic reviews/meta-analyses, RCTs, and prospective, nonrandomized comparative studies that examined commercially available skin substitutes in individuals with DFUs, venous leg ulcers, pressure ulcers, and arterial leg ulcers were included in the review. Overall, 76 commercially available skin substitutes were identified and categorized based on the Davison-Kotler classification system. In total, 68 (89 percent) were categorized as acellular dermal substitutes, mostly replacements from human placental membranes and animal tissue sources. Three systematic reviews and 22 RCTs examined the use of 16 distinct skin substitutes, including acellular dermal substitutes, cellular dermal substitutes, and cellular epidermal and dermal substitutes in DFUs, pressure ulcers, and venous leg ulcers. Overall, 21 ongoing clinical trials (all RCTs) examined an additional nine skin substitutes with comparable classifications. EPIFIX was reviewed in five studies. GRAFIX/GRAFIX PRIME, MatriStem Wound Matrix/MatriStem MicroMatrix, TheraSkin, and DermACELL were all reviewed in two studies each. The findings of the review included the following:
  • While 85 percent of studies examining acellular dermal substitutes described the experimental intervention as favorable over SOC for wound healing and shorter healing time, insufficient data are available to determine whether wound recurrence or other sequela are less frequent with acellular dermal substitutes. Only three studies compared cellular dermal substitutes with SOC. Clinical evidence for cellular dermal substitutes may be limited by the lack of robust, well-controlled clinical trials of these products in this category.
  • Of the six head-to-head, comparative studies, findings from five studies did not indicate significant differences between skin substitutes in outcomes measured at the latest follow-up (>12 weeks). The investigators concluded that the current evidence base may be insufficient to determine whether one skin substitute product is superior to another.
  • The investigators found little information on the long-term effects of using skin substitutes. Wound recurrence was seldom reported, and potential toxic and carcinogenic effects are not known. Information on amputations and hospitalizations due to infections is also missing. Before findings can be relied on, more data are needed on hospitalization, pain reduction, need for amputation, exudate, odor control, and return to baseline activities of daily living and function.
  • The investigators indicated that variation in study designs reduces the ability to compare outcomes across studies. For example, the investigators identified 20 different criteria in 38 (published and ongoing) studies that reported a wound size inclusion criterion. Sizes ranged from as small as 0.5 to 100 cm2. Overall, 1 to 25 cm2 was the most common range used as a wound size inclusion criterion. More than 4 weeks was the most common wound duration inclusion criterion (25 studies), while a few studies allowed up to 52 weeks. Only six published studies reported on wound recurrence after 12 weeks. Given the variation in these and other study design features, the investigators indicated that research in this field may benefit from a more standardized study design.
  • The investigators found that the industry sponsored 20 of 22 RCTs included in this report, which raises significant concerns about publication bias and selective outcome reporting; results unfavorable to the industry may not have been reported or published.
According to the investigators, this technical brief’s clearest implications are the lack of studies examining the efficacy of most skin substitute products and need for better-designed studies that provide more clinically relevant data. The investigators indicated that future studies may be improved by using a 4-week run-in period before study enrollment and at least a 12-week study period. Future studies should also report whether wounds recur during the 6-month follow-up.

Á​lvaro-Afonso et al. (2020) reviewed the recent advances in dermoepidermal skin substitutes (DSSs) for the treatment of DFUs. The PubMed and Cochrane databases were systematically searched for systematic reviews published after 2013 and for RCTs. A retrospective evaluation of 28 RCTs was performed, without meta-analysis. Four of these used EPIFIX, including three that compared it with SOC, with two also reviewed in the Sui et al. systematic review reported above. Rates of complete wound closure and time to healing were examined for 17 commonly available DSSs. Healing rates after 12 weeks and time to complete closure of DFUs were heterogeneous among the 28 RCTs. The best healing rates at 12 weeks were accomplished with dermal cellular substitutes (EPIFIX, 100 percent; AmnioBand, 85 percent). The authors concluded that based on these studies, DSSs used in conjunction with standard care appear to improve the healing rates of DFUs compared with standard care alone. The authors indicated that new studies with more homogeneous samples are needed to ascertain the role of ulcer size, duration, depth, and/or type in the efficacy of DSSs. According to the authors, future RCTs should include individuals with severe comorbidities to be more representative of clinical reality. Gordon et al. (2019) conducted a systematic review to determine the efficacy of biological skin substitutes for healing DFUs. Some products included in this review were AmnioExcel, DermACELL, EPICORD, EPIFIX, GRAFIX, MatriStem, and TheraSkin. The main objective was to calculate a pooled risk ratio for the proportion of wounds completely closed by 12 weeks. Secondary objectives included a pooled risk ratio for the proportion of wounds completely closed by 6 weeks and the mean time to healing. Biological skin substitutes were organized both very specifically into product brand and more broadly by four main groups based on product composition: allografts/xenografts, cultured skin grafts, dermal substitutes, and biosynthetic dressings. Overall, 25 studies were identified that assessed the proportion of complete wound closure by 12 weeks. Wounds treated with biological dressings were 1.67 times more likely to heal by 12 weeks than those treated with SOC dressings (P<0.00001). Five studies assessed the proportion of complete wound closure by 6 weeks. Wounds treated with biological dressings were 2.81 times more likely to heal by 6 weeks than those treated with SOC dressings (P=0.0001). Descriptively, 29 of 31 studies that assessed time to healing favored biological dressings over SOC dressings. Cultured skin grafts did not show a statistical difference over SOC. The authors concluded that this systematic review provides supporting evidence that biological skin substitutes are more effective than SOC dressings at healing DFUs by 12 weeks. This review has several study limitations, one being that the individual products were assessed in only one or two studies. Complete wound healing was assessed at 12 weeks, but the mean time to healing in that time periods was not assessed. Finally, adverse effects of skin products were not mentioned. Future studies must address the relative benefits of different skin substitutes as well as the long-term implications of these products.


Abdominal Wall Reconstruction: Following a systematic review of 40 studies (37 retrospective reviews), Janis et al. (2012) concluded that there is a lack of high-level data to define the precise role of acellular dermal matrix (ADM) and guidelines for its use for abdominal reconstruction guidelines. Hernia recurrence, the primary outcome measure, ranged from 0 to 80 percent. Limitations of the studies included small, heterogeneous individual populations (n=5–240); short-term follow-ups (0–68 months); heterogeneity in surgical techniques; variable starting points of the studies; wide variety of clinical indications for reconstruction (e.g., ventral hernia; incisional hernia, abdominal compartment syndrome, tumor resection, fascial defects, contaminated abdominal wall); variety of positions of matrices; conflicting reports regarding superiority of underlay versus overlay techniques; variety in the number of matrix layers used; and use of matrices in combinations with other techniques making it difficult to evaluate the benefit of the matrix alone. Zhong et al. (2011) conducted a systematic review to evaluate the evidence on ADM used during abdominal wall reconstruction. Thirty case series (n=4) and retrospective reviews (n=26) met inclusion criteria. No RCTs or systematic reviews were found. Studies included the use of porcine ADM and human ADM. The outcomes studied included hernia recurrence, abdominal wall laxity, delayed wound healing, infection and seroma. The incidence of postoperative/recurrent hernia ranged from 0 to 80 percent, and the incidence of abdominal wall laxity was largely unreported. Delayed healing occurred in up to 64 percent of individuals with infection-related complications (e.g., surgical site infections, cellulitis, deep/intrabdominal abscesses) reported as high as 40 percent. Types of ADM, technique, and types of fascia repair and suture used varied. The authors concluded that there was a paucity of high-level evidence comparing ADM with other methods, interfering with the ability of physicians to make data-driven recommendations on clinical indications, surgical techniques and outcomes following ADM-assisted abdominal wall reconstruction.

Amniotic Allografts for Use in Bariatric and Gynecological Procedures: Abstracts included a Cochrane review (Bosteels et al., 2017) on antiadhesion therapy following operative hysteroscopy for treatment of female subfertility. Studies using HAM grafting versus no grafting were included. The authors concluded that the clinical effectiveness of antiadhesion treatment for improving key reproductive outcomes or for decreasing intrauterine adhesions (IUAs) following operative hysteroscopy in subfertile women remained uncertain. A pilot RCT (n=45) of women with severe adhesions allocated the women to one of three groups: insertion of intrauterine balloon only, fresh amnion graft, or dried amnion graft. Outcomes were significantly better with amnion graft than intrauterine balloon alone (P=0.003) and outcomes were better with fresh amnion than with dried amnion (P=0.01). Additional studies with larger individual populations are needed to validate the effectiveness of amniotic graft for this indication. No evidence was found to support the use of amniotic membrane in bariatric surgery.

Dural Sealants: Kinaci et al. (2018) conducted a systematic review of the literature to evaluate the efficacy of dural sealants in preventing cerebrospinal fluid (CSF) leakage following cranial surgery. Studies describing regular cranial procedures combined with the use of any dural sealant reporting CSF leakage were included. The primary outcome measure was CSF leakage of any origin. Secondary outcomes were incidental leakage through the skin, pseudomeningocele formation (subcutaneous or epidural collection of CSF) and surgical-site infection. Twenty studies (n=3682 procedures) met inclusion criteria and were primarily in the form of retrospective reviews and case series. Ten comparative studies (n=2321), including three RCTs, comparing sealant versus no sealant were included in the meta-analysis. There was no significant difference between the two groups in CSF leakage. Meta-analyses for secondary outcomes showed no significant difference between the number of incisional CSF leakages or in the pseudomeningocele formation. Surgical-site infection was seen less in the sealant group than the control group. The number of individuals with surgical-site infection in the sealant group was 10 of 1006 (1.0 percent) versus 60 of 1062 (5.6 percent) in the control group. Overall, adverse events were not reported and when they were, the direct relationship between sealant use and adverse event was not objectively confirmed. Author-noted limitations of this systematic review included lack of RCTs; individuals receiving rescue therapy in the control group with other types of sealants or grafts to obtain watertight closure were not excluded; high risk of bias in the comparative cohort studies; heterogeneity of the individual populations and sealants used; variation in the number of CSF leakages; and differentiation in leakage between supra- and infratentorial craniotomies could not be made. The authors concluded that studies with greater methodologic quality including RCTs are warranted.

Fibrin Sealants: Esposito et al. (2016) conducted a systematic review of the literature to investigate the safety and efficacy of fibrin sealants that are used as dural sealants to prevent and/or treat CSF leaks. Thirty-two studies enrolled 2935 individuals who were exposed to fibrin sealant. Seven studies that only included safety data were included and used for safety analysis. Three studies were RCTs. The remaining studies were prospective case series and retrospective reviews. The studies investigated fibrin glue for the treatment of acute intraoperative CSF leaks, prevention of postoperative CSF leaks, and treatment of persisting CSF leaks. Overall, few or no adverse events were reported in most of the studies. Limitations of the studies included limited number of RCTs, heterogeneity in the definition of postoperative CSF leak, limited number of studies (n=2) that discussed fibrin sealants for persistent CSF leaks, variations in surgical technique, variety of fibrin glues that were used did not allow comparison of products, heterogeneity in individual populations (e.g., age, sex, race, medical condition), and variation in use of secondary treatments (i.e., medical therapies, interventional strategies). Because of the limitations of the studies, firm conclusions could not be made regarding the benefit of fibrin sealants. Well-designed and powered randomized clinical trials are needed to support the safety and establish the efficacy of these sealants.

Fistula Plugs: Nasseri et al. (2016) conducted a systematic review to evaluate the evidence on the efficacy of anal fistula plugs (AFPs) in treating fistula-in-ano in individuals with Crohn’s disease. Twelve studies met inclusion criteria. Eight were nonrandomized prospective and four were retrospective reviews. Eighty-four individuals (n=1–20 per study), age between 18 and 72 years (median, 45 years) and follow-up between 3 and 24 months (median, 9 months) were included in the analysis. The total success rate (i.e., closure of the fistula tract) was achieved in 49 of 84 individuals. Two of five individuals had success with recurrent fistula. The overall success rate with Surgisis was 48 of 80 and one of four individuals for Gore Bio-A. Five studies reported a recurrence rate of 13.6 percent (3/22 individuals). The authors were unable to draw firm conclusions due to the limitations of the studies. The procedure appeared safe with little morbidity and low risk of incontinence. Limitations of the studies as noted by the authors included heterogeneity of study design; small individual population; lack of statistical significance in outcomes; grouping of fistulas in Crohn’s disease with other types of anal fistulas, thus introducing ambiguity; short-term follow-up and heterogeneity of follow-up times; and various confounding factors (e.g., use of steroids or immunosuppressants, previous use of seton stitch to aid in healing and variation in surgical technique) and lack of reporting of these factors. The authors noted that the outcomes may have been worse if longer follow-ups had been reported and that it was unclear whether failure occurred as a result of technical error or owing to the pathology of the fistula despite use of the correct surgical technique. In a systematic review, O’Riordan et al. (2012) identified 56 articles that investigated anal fistula plugs for the treatment of Crohn’s (n=42) and non-Crohn’s disease (n=488). Eight studies were retrospective, 10 were prospective cohorts, and two were RCTs. Individual population ranged between four and 60 individuals. Included studies involved individuals with and without Crohn’s disease that could be differentiated and a mean or median follow-up of 3 months or greater. The longest follow-up was 24.5 months. Individuals with rectovaginal, anovaginal, rectourethral, or ileal-pouch vaginal fistulas were excluded. Overall, plug extrusion rate was 8.7 percent (n=46). In individuals with non-Crohn’s disease, fistula closure ranged between 0.2 and 0.86. The overall success rate for individuals with Crohn’s was 54.8 percent (23 of 42 individuals) and 54.3 percent of individuals (265 of 488 individuals) without Crohn’s disease. Limitations of the study included heterogeneity of operative technique, perioperative care; operative position, and anesthesia type; and the retrospective and noncomparative study designs.

Hernia Repairs: Trippoli et al. (2018) conducted a systematic review of the literature to evaluate the differences in various biological products for the treatment of primary and incisional ventral hernias. Included studies met the following criteria: treatment of primary and incisional abdominal hernia; mesh derived from porcine dermis or porcine intestinal submucosa or bovine pericardium or bovine or fetal dermis; may or may not involve "cross-linking of collagen;" the end-point was 30-day follow-up of surgical site infection and/or relapse rate after follow-up of at least 12 months. The five available biological meshes of porcine derivative available in the market at the time of the analysis were Strattice, Permacol, Fortiva, Surgisis, and Xenmatrix. The four available bovine meshes were Peri-guard, Veritas, Bioripar, and Tutomesh. Eleven trials that evaluated five meshes met inclusion criteria. Nine studies were single-arm (prospective or retrospective), and two studies were based on a comparative design. The meshes included in the studies were Permacol (n=706), Strattice (n=324), Surgisis (n=44), Tutomesh (n=38) and Xenmatrix (n=22). No published studies were found investigating Fortiva, Veritas, Bioripar, and Tutomesh. Among all comparisons carried out within these biological meshes, one significant difference was found. Permacol (a crosslinked mesh) showed a lower recurrence rate at 12 months than Strattice (a non-cross-linked mesh) (P=0.001), suggesting that crosslinking may strengthen a mesh. Overall the studies generally showed a poor methodological quality. There was wide variability in the surgical wound infections between studies and the 12-month relapse rates (n=4 studies). Additional author-noted limitations of the studies included the limited available clinical information, small individual populations, short-term follow-ups, and uncontrolled study designs. Other limitations are the heterogeneity of the wound types and retrospective study designs. In conclusion, there is insufficient evidence in the published literature to support the use of biological mesh for hernia repair. Data do not indicate if a porcine versus bovine or cross-linked versus noncrosslinked mesh should be used. Individual selection criteria have not been established.

In a 2014 systematic review, Cross et al. reported that the data for biological mesh products in ventral hernia repair in contaminated fields were limited. Sixteen studies (n=554) met inclusion criteria. All of the studies were case series with the largest individual population being 116. Six different mesh products were used. The authors recommended that caution be used when considering the use of biological meshes because there is a paucity of controlled trials and none of the products are FDA approved for this indication.

Ferzoco (2013) conducted a systematic review to assess outcome in individuals who underwent repair of contaminated or infected ventral incisional hernias using a biologic mesh. The 11 studies that met inclusion criteria used the following products: AlloDerm (n=7), Surgisis (n=2); CollaMend (n=2), Permacol (n=2), Strattice (n=1), and Veritas (n=1). All studies were retrospective chart reviews and included a total of 677 individuals. Reported hernia recurrence varied widely and ranged between 0 and 50 percent. Wound dehiscence rates varied between 0 and 35.5 percent and mesh explantation ranged between 0 and 23 percent. Occurrence rates for seroma, fistula, evisceration, intrabdominal bleeding, repeat surgery, and hematoma were typically not reported. The most commonly reported reasons for a secondary surgical procedure included repair of recurrent hernia, mesh removal, drainage of seroma, and drainage of surgical site abscess. Prospective studies are needed to investigate the efficacy of biologic mesh in the treatment of infected ventral incisional hernias.

Beale et al. (2012) conducted a systematic review to evaluate the use of biological mesh in the repair of ventral hernias in adults. Twenty-nine studies met inclusion criteria (n=1257). Four studies used Permacol (n=64), three used Surgisis (n=87), and 23 used AlloDerm (n=1106). Primary outcomes were hernia recurrence and surgical site occurrences (hematoma, seroma, wound infection, dehiscence or graft removal).  Device-specific recurrence rates were 20.8 percent​ for AlloDerm, 10.9 percent for Permacol, and 8.0 percent for Surgisis. The surgical site occurrence rate (e.g., hematoma, seroma, wound, infection, dehiscence, or need for graft removal) was 31.4 percent for AlloDerm, 25 percent for Permacol, and 40.2 percent. The authors noted that it was difficult to identify a uniformly accepted technique for the placement of the biologic mesh. Limitations of the studies included retrospective study design (n=27 studies), heterogeneity of surgical technique and placement of the product, lack of reporting of hernia recurrence and complication rates, paucity of data, and older studies. Well-designed, prospective RCTs with large individual populations and long-term follow-up are needed to evaluate biological mesh for ventral hernia repair.


Kissane and Itani (2012) conducted a systematic review to evaluate ADM for complex ventral incisional hernia repair. Eight single-center studies (n=635) met inclusion criteria and used either AlloDerm (n=461), Surgisis (“Sis-ECM” mesh) (n=91), or Strattice (n=80). One study was prospective and used Strattice in a one-stage repair of infected or contaminated hernias. Seven studies were retrospective in design. There was a recurrence rate of 21 percent after 25.8 months; the highest rate was observed in the AlloDerm individuals. Total percentage of complications (e.g., wound-related, eventration, mesh rejection) in the AlloDerm hernia repairs was 40.4 percent. Other complications included seroma formation, postoperative peritonitis, subfascial abscesses, intra-abdominal hematoma, and mesh reaction. Because of the heterogeneity of the individual population, ventral incisional hernia grades, type of meshes used, surgical techniques, and length of follow-up, a meta-analysis could not performed. Other limitations of the studies included minimal reporting of individual inclusion criteria and demographics, diverse individual comorbidities, retrospective study designs, lack of controls, and short-term follow-up (mean, 25.8 months).

Smart et al. (2012) conducted a systematic review to assess the clinical outcomes of biological meshes used in abdominal wall hernia repairs. Forty-five RCTs, case series, and retrospective reviews met inclusion criteria including 23 studies on AlloDerm, seven on Surgisis, 10 on Permacol, and seven on other meshes. Most articles were retrospective reviews or uncontrolled prospective case series with small heterogeneous, individual populations, poorly described methodology, and short-term follow-ups (3–52 months). AlloDerm recurrence rates ranged from 0 to 100 percent and were inferior compared to polypropylene and Surgisis. In infected fields, recurrence rates were high at short and medium-term follow-up. Concerns were reported regarding bulging at the repair site and stretching of the graft. "There is little evidence to support the use of AlloDerm in most of the situation where a biological mesh is indicated." The recurrence rates with Permacol were 0 to 15 percent. Outcomes in Permacol studies were conflicting and “important methodological weaknesses exist” representing a low level of evidence. Outcomes with Surgisis were also conflicting. Some studies reported a recurrence rate of 0 to 5.3 percent regardless of whether the surgery was performed in a clean or infected field, whereas other studies reported a recurrence rate as high as 39 percent​ in dirty fields. One study was terminated early due to the high recurrence rates in a Surgisis group with clean cases. According to the authors, insufficient or minimal data in the form of retrospective reviews were found for Veritas, Xenmatrix, CollaMend, and Strattice, and only case reports were found for Allomax, FlexHD, FortaGen, Peri-Guard, SurgiMend and Tutopatch.

Hyaluronic Acid: Shaharudin and Aziz (2016) conducted a systematic review to assess the evidence on the effectiveness of hyaluronic acid compared to placebo or other agents for promoting chronic wound healing. Nine RCTs (n=865) met inclusion criteria. The authors noted that there was better quality of evidence for mixed arterial and venous ulcers than for venous leg ulcers and DFUs. Overall, the studies provided little evidence regarding the claimed effects of hyaluronic acid for this indication. Some mixed evidence suggested that hyaluronic acid reduced the intensity of pain for mixed arterial and venous ulcers. There is insufficient evidence to support the use of hyaluronic acid​ for the treatment of chronic wound healing.

Laryngotracheal and Pharyngeal Reconstruction: Hui et al. (2017) conducted a systematic review to evaluate the safety and efficacy of acellular dermal matrices in laryngotracheal and pharyngeal reconstruction. Eleven studies (n=170) including three retrospective review, five case series, and three case reports met inclusion criteria. Eight studies reported on ADM use in oncological reconstruction. Seven studies used AlloDerm, three studies used Heal-All Oral Biofilm (Zhenghai Biotech, Yantai, China) and one case report used Permacol. Follow-ups varied between 2 weeks and 42 months. The methodology of the studies was poor. Other limitations included the small individual populations, and heterogeneity of surgical procedures and diagnosis. Overall, the studies provided incomplete descriptive detail concerning perioperative radiation dosing and scheduling, the surgeon’s experience using dermal grafts, graft thickness, and defect size. The authors stated that because of the limited number and heterogeneity of the cases, conclusions could not be made regarding the impact of ADM use on postoperative stricture and stenosis rates in tracheal or pharyngeal reconstruction.

Orthopedic Sports Medicine: Riboh et al. (2016) conducted a systematic review of the literature to assess the evidence for amniotic membrane products used in orthopedic sports medicine. Eighty articles were considered relevant to the study. Fifty-five of the articles were narrative and 25 articles described preclinical and clinical trials of amniotic products for orthopedic sports medicine. The primary indications explored included cartilage restoration, ligament and tendon healing, nonoperative treatment of knee osteoarthritis, and plantar fasciitis. Because of the low quality of the studies, a systematic review summary and meta-analysis for the use of these products for this indication could not be conducted. According to the authors the current body of evidence is heavily biased toward in vitro and animal studies, with little to no human clinical data.

Tendon and Ligament Repairs: Chen et al. (2009) conducted a systematic review of biological and synthetic scaffolds used for tendon and ligament repairs. Of 378 identified articles, 47 clinical trials met inclusion criteria. Of the 47 articles, 16 clinical trials included four commercial biological scaffolds (i.e., five included the use of Restore, six used GraftJacket, four used Zimmer [formerly Permacol], and one study included both Restore and GraftJacket. After a review of the data, the authors reported the following:
  • Restore – “Restore or scaffolds from small intestine submucosal are ineffective in the reinforcement of large rotator cuff tears and currently not recommended for use in cuff tendon repair.” They identified other scaffolds made from small intestine submucosal (i.e., Oasis, Surgisis, and CuffPatch™ [Organogenesis, Inc., Canton, MA]) and stated that “extra care should be taken to monitor adverse events when applied in individuals.”
  • GraftJacket – “Satisfactory results have been described using GraftJacket for skin lesion and abdominal wall repair.” No reports of inflammatory response, edema or postoperative infection have been reported, and individuals seemed to tolerate it well. However, recurrent tears were noted in 30 percent of individuals in two studies.
  • Zimmer (Permacol) – Two retrospective reviews (n=10 each) reported increased pain relief and range-of-motion following implantation, but two other smaller studies reported recurrent tears, aggravated pain and decrease range-of-motion. Foreign body reaction was noted in several of the individuals.
  • TissueMend – No published animal or clinical studies were found. They noted that TissueMend has been reported to contain higher genetic materials compared to other products which raise concern regarding human application. 
  • OrthADAPT – No published animal or clinical studies could be found
According to Chen et al., the studies in this systematic review were primarily in the form of case reports, case series, or retrospective reviews and limited by small individual populations (n=1–30), short-term follow-ups (3 months–5 years) and lack of comparison to established methods of treatment. One of the major concerns with these products is biocompatibility and inflammatory response associated with foreign body rejection. The authors also noted that many scaffolds were FDA approved without proper animal studies or evidence-based clinical trials.

  • For individuals who are undergoing breast reconstruction who receive allogeneic ADM products, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, morbid events, functional outcomes, QOL, and treatment-related morbidity. A systematic review found no difference in overall complication rates with ADM allograft compared with standard procedures for breast reconstruction. Reconstructions with ADM have been reported to have higher seroma, infection, and necrosis rates than reconstructions without ADM. However, capsular contracture and malposition of implants may be reduced. Thus, in cases where there is limited tissue coverage, the available evidence may inform individual decision making about reconstruction options. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.
  • For individuals who are undergoing tendon repair who receive GraftJacket, the evidence includes an RCT. Relevant outcomes are symptoms, morbid events, functional outcomes, QOL, and treatment-related morbidity. The RCT identified found improved outcomes with the GraftJacket ADM allograft for rotator cuff repair. Although these results were positive, additional studies with a larger number of individuals is needed to evaluate the consistency of the effect. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
  • For individuals who are undergoing surgical repair of hernias or parastomal reinforcement who receive acellular collagen–based scaffolds, the evidence includes RCTs. Relevant outcomes are symptoms, morbid events, functional outcomes, QOL, and treatment-related morbidity. Several comparative studies including RCTs have shown no difference in outcomes between tissue-engineered skin substitutes and either standard synthetic mesh or no reinforcement. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
  • For individuals who have diabetic lower extremity ulcers who receive AlloPatch, Apligraf, Dermagraft, Integra, mVASC, or TheraSkin, the evidence includes RCTs. Relevant outcomes are symptoms, change in disease status, morbid events, and QOL. RCTs reporting complete wound healing outcomes with at least 12 weeks of follow-up have demonstrated the efficacy of AlloPatch (reticular ADM), Apligraf, and Dermagraft (living cell therapy), Integra (biosynthetic), mVASC, TheraSkin, and Omega3 Wound (Kerecis) over the SOC. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.
  • For individuals who have diabetic lower extremity ulcers who receive bioengineered skin substitutes other than AlloPatch, Apligraf, Dermagraft, Integra, mVASC, TheraSkin, or Omega3 Wound, the evidence includes RCTs. Relevant outcomes are symptoms, change in disease status, morbid events, and QOL. Results from a multicenter RCT showed some benefit of DermACELL that was primarily for the subgroup of individuals who only required a single application of the ADM. Studies are needed to further define the population who might benefit from this treatment. Additional study with a larger number of subjects is needed to evaluate the effect of GraftJacket, DermACELL, Cytal, PriMatrix, and Oasis Wound Matrix, compared with current SOC or other advanced wound therapies. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
  • For individuals who have lower extremity ulcers due to venous insufficiency who receive Apligraf or Oasis Wound Matrix, the evidence includes RCTs. Relevant outcomes are symptoms, change in disease status, morbid events, and QOL. RCTs have demonstrated the efficacy of Apligraf living cell therapy and xenogeneic Oasis Wound Matrix over the SOC. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.
  • For individuals who have lower extremity ulcers due to venous insufficiency who receive bioengineered skin substitutes other than Apligraf or Oasis Wound Matrix, the evidence includes RCTs. Relevant outcomes are disease-specific survival, symptoms, change in disease status, morbid events, and QOL. In a moderately large RCT, Dermagraft was not shown to be more effective than controls for the primary or secondary endpoints in the entire population and was only slightly more effective than controls (an 8 percent to 15 percent increase in healing) in subgroups of individuals with ulcer durations of 12 months or less or size of 10 cm or less. Additional studies with a larger number of subjects is needed to evaluate the effect of the xenogeneic PriMatrix skin substitute versus the current SOC. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
  • For individuals who have deep dermal burns who receive bioengineered skin substitutes (i.e., Epicel, Integra Dermal Regeneration Template), the evidence includes RCTs. Relevant outcomes are symptoms, change in disease status, morbid events, functional outcomes, QOL, and treatment-related morbidity. Overall, few skin substitutes have been approved, and the evidence is limited for each product. Epicel (living cell therapy) has received FDA approval under a HDE for the treatment of deep dermal or full-thickness burns comprising a total body surface area of 30 percent or more. Comparative studies have demonstrated improved outcomes for biosynthetic skin substitute Integra Dermal Regeneration Template for the treatment of burns.
    • Epicel (Vericel Corporation, Cambridge, MA) is a cultured epidermal autograft (CEA) that is FDA approved under the HDE process for individuals who have deep dermal or full-thickness burns comprising a total body surface area of greater than or equal to 30 percent (Vericel Corporation, 2025). It may be used in conjunction with split-thickness autografts or alone in individuals for whom split thickness autografts may not be an option (FDA, 2007). Epicel is FDA approved as a HDE device. Prospective comparative studies and case series support Epicel for the treatment of burns (Carson et al., 2003; Munster, 1996). The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.
  • For individuals who have deep dermal burns who are treated with the ReCell autologous cell harvesting device, the evidence includes RCTs. One RCT evaluated ReCell as an adjunct to meshed autologous skin grafting and the other compared ReCell head-to-head with skin grafting. Although the ReCell device was comparable to standard care on outcomes such as complete wound closure, confidence in the strength of the overall body of evidence is limited by individual study limitations and heterogeneity of populations, interventions, and outcome measures across studies. Additional RCT evidence in the intended use population is needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
  • For individuals who have dystrophic epidermolysis bullosa who receive OrCel, the evidence includes a case series. Relevant outcomes are symptoms, change in disease status, morbid events, and QOL. OrCel was approved under a humanitarian drug exemption for use in individuals with dystrophic epidermolysis bullosa undergoing hand reconstruction surgery, to close and heal wounds created by the surgery, including those at donor sites. Outcomes have been reported in a small series (e.g., five individuals). The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
    • OrCel (Forticell Bioscience, Inc., New York, NY) is an allogeneic, bilayered cellular matrix, type I bovine collagen sponge with FDA PMA approval for the treatment of split-thickness donor site wounds in burn individuals. There is limited evidence to support the efficacy of Orcel compared to the SOC for the treatment of split-thickness donor sites. Therefore, OrCel is considered investigational for this indication. FDA-HDE approval (H990013) was granted for OrCel for use as an adjunct in the treatment of mitten-hand deformity surgery of epidermolysis bullosa. Published studies are in the form of case series with small individual populations (n=7). There is insufficient evidence to support the use of Orcel for any indication. In a matched-pairs study conducted by Still et al. (2003), the use of OrCel was compared to treatment with Biobrane L. Eighty-two severely burned individuals each had two designated split thickness donor sites of equivalent surface area and depth. Sites were randomized to receive a single treatment of either OrCel or the standard dressing, Biobrane-L. Sites were evaluated for wound closure. The researchers found a statistically significant decrease in healing time with the use of OrCel compared to Biobrane L. There was a decrease in scarring associated with the use of OrCel, although it was not statistically significant. Additional clinical trials are needed to validate the findings of this study.
The data on skin substitute usage for managing Mohs micrographic surgery (MMS) wounds remain limited. The most commonly used skin substitute for this purported indication within reliable data sources had been porcine collagen. Bovine collagen, Integra, Hyalofill, amnion/chorion-derived grafts, and allogeneic epidermal-dermal composite grafts are also reported in limited capacity and in a significantly lower quality—relative to porcine collagen—within peer-reviewed and published literature. Common factors influencing skin substitute selection appear to be cost, healing efficacy, cosmetic outcome, individual comfort, and ease of use. There are pertinent published articles in the available literature that did not specify individual and wound characteristics. Comprehensive review and assessment of evidence lead to the deduction that skin substitute usage in MMS reconstruction is not well-guided. Blinded RCTs comparing the efficacy of skin substitutes and traditional repair methods are imperative for establishing evidence-based guidelines on skin substitute usage following MMS.

For example, the peer-reviewed and published evidence for Integra consists of low-quality retrospective data of different biased and limited designs, which preclude making any definitive deductions about the safety and effectiveness of this technology. There is a paucity of reliable evidence for Integra for post-Mohs surgery; however, the overall data for multiple versions of this product for several other purported indications (e.g., Bascone et al., 2023; Maus et al., 2021; Othman et al., 2021; Mogedas-Vegara et al., 2021; Locurcio et al., 2023; Reece et al., 2023; Bassetto et al., 2025) also present with insufficiencies in evidence regarding sustained and relevant health improvements. The retrospective study design of pertinent publications confers heterogeneous bias in data collection. A smaller sample size and nonparametrically distributed data in these studies in the failure groups very likely limits the ability to detect clinically significant findings, such as the differences in wound age, and larger studies are warranted. Furthermore, the length of stay could not adequately be captured in these studies due to many subjects being involved in immediate, ambulatory procedures. In the available data, specific individual factors were underpowered for the detection of correlation with failure. For example, increased age, smoking history, and diabetes are known obstacles to wound healing and the small number of subjects with a positive history of each may have resulted in a lack of identification as correlative risk factors for failure. Furthermore, the small sample sizes in the failure groups also confer bias to any documented results.

Among others, one of the reported main drawbacks of Integra is the need to perform a second intervention to carry out a split-thickness skin graft. Soft tissue defects created by wide local excision are capable of producing bigger depth discrepancies and larger dermal violations than those created by MMS. Thus, it is possible for the chances of contour deformity to be greater if Integra is applied in this setting, in addition to an increased latency period to second-stage reconstruction while waiting for the defect to fill in with granulation tissue. It was acknowledged in the clinical research that in the facial region, deeper defects (which suffer a great loss in cartilage) sometimes require more adequate structural support and tissue bulk from a free or local flap, to overcome more severe contracture. Limitations of studies also include failure to include analysis of adjuvant therapy and its effect on construct durability. Individuals receiving adjuvant therapy in studies were few in number and had insufficient follow-up or escalation of reconstruction, making meaningful analyses difficult. Furthermore, certain variables were surgeon dependent in studies (choice of dressing modality, clinical evaluation of graft take). Larger, prospective studies with randomization and analysis of adjuvant therapies are needed. Additionally, studies fail to include a matched individual group receiving flap reconstruction, analyze cosmetic outcomes, and address related clinical factors. It should be noted that, typically, there was differential skin graft adherence between the full-thickness wound groups (which necessitated burring of outer-table bone prior to Integra placement) and the partial-thickness cohorts. Therefore, larger studies would be useful to clarify this difference and corroborate any encouraging clinical outcomes that continue to only be reported in low-quality reliable evidence.

Helicoll® HeliColl (EnColl Corporation, Fremont, CA) is a semi-occlusive, self-adhering, acellular, type 1 collagen graft proposed for wound care (EnColl, 2026). It is derived from a bovine or ovine source. The product is FDA 510(k) approved for topical wound management including partial and full thickness wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, diabetic ulcers, trauma wounds (abrasions, lacerations, second-degree burns, skin tears) and surgical wounds (donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence). It was approved as a predicate device to existing similar products. According to EnColl, healing occurs within one to four applications. HeliColl comes in multiple sizes ranging from 1 square cm to 50 square cm (WoundSource, 2025; Dhanraj, 2015; FDA, 2004). Data supporting the safety and efficacy of HeliColl is lacking. There are limited studies related to Helicoll for wound treatments, second-degree burns, and chronic ulcers. Therefore, it is not possible to determine whether Helicoll has a beneficial effect on health outcomes. Helicoll (MCT Medical Solutions LLC) is a semiocclusive, self-adhering collagen sheet that is used for wound treatments, second-degree burns, and chronic ulcers. This biodegradable skin substitute is made from animal tissues. In an evidence-based review, McNamara et al. (2020) discussed the principles of pediatric wound management and new treatments that were published in the literature to date. Databases were searched for relevant sources, including PubMed, Embase, Web of Science, and DynaMed. The findings noted that amniotic membrane living skin equivalent is a cellular matrix that has been reportedly successful in treating pediatric wounds and is currently under investigation in randomized clinical trials. The authors indicated that Helicoll, an acellular matrix, shows promise in children with recessive dystrophic epidermolysis bullosa. According to the authors, there have been promising results in many studies to date, but RCTs that involve larger sample sizes are necessary to (1) determine the specific role that these advanced products play in pediatric wounds, and (2) identify their safety and efficacy. Dhanraj et al. (2015) conducted a prospective RCT to compare Helicoll, a type I pure collagen dressing, with OPSITE dressing and with scarlet red dressing in the treatment of standardized STSG donor sites. Overall, 30 participants, over a 3-month period, underwent various reconstructive procedures, necessitating the use of STSGs. Following a simple randomized clinical protocol, the analysis of data included donor site pain, the healing time of the donor site, the initial absorption of the applied dressing, and the rate of infection with the three different dressings. Compared with the OPSITE and scarlet red dressing groups, participants in the Helicoll group reported significantly less pain and a decreased infection rate, and they required no dressing change. The healing time of the donor site in the Helicoll group was shorter than that in the scarlet red group; however, it was comparable to that in the OPSITE group. The authors concluded that Helicoll, as a donor site dressing, is successful in providing pain-free mobility, with a measurable healing rate. Study limitations include a small study population and the fact that only one wound type (STSG donor site) was evaluated.

Integra Flowable Wound Matrix (Integra Lifesciences, Princeton, NJ) is a granulated, acellular bovine tendon collagen and glycosaminoglycan device that is 510(k) FDA (K072113) approved for the treatment of advanced wound care. The granulates are reconstituted with saline to form a gel-like substance. The matrix is considered “substantially equivalent in function and intended use to Integra Matrix Wound Dressing” and is approved for the treatment of “partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears) and draining wounds” (Integra LifeSciences, 2026; FDA, 2007). The skin substitute is packaged in a syringe and intended for one time use. There is insufficient evidence in the published peer-reviewed scientific literature supporting the efficacy of Integra Flowable Wound Matrix. Campitiello et al. (2017) conducted a randomized, placebo-controlled trial to evaluate the efficacy of Integra Flowable Wound Matrix (n=23) compared with a wet dressing (n=23) for the treatment of DFUs with irregular geometries (tunneling or cavity lesions). Inclusion criteria were diabetic individuals, age greater than 18 years, who had grade 3 Wagner classification DFUs with an ankle-brachial index (ABI) of​ 0.5 or greater. Antibiotic therapy was started 7 to 10 days prior to surgery and continued until the wound had healed. The primary objective of the study was to determine the percentage of individuals with wound closure (100 percent re-epithelialization). Secondary outcome measures included the time to healing and safety (number of major amputations and hospitalizations). Wounds were cleaned and necrotic tissue was removed until normal healthy tissues appeared. After mixing the dry granular collagen with saline solution, the matrix was applied to the lesion, until completely filled. The edge of the wound was sutured. Wounds in the control group were covered with a sterile saline-moistened gauze before the dressing was applied. Compression dressings and offloading devices were used by both groups. Individuals were followed until complete wound healing had occurred or for up to six weeks. Healing was determined by clinical examination and complete healing was defined as 100 percent re-epithelialization in the absence of discharge. At 6 weeks, complete healing had occurred in significantly more Integra individuals (n=20; 86.95 percent) than control group individuals (n=12; 52.17 percent) (P=0.001). Healing time was significantly shorter in the study group, for which the surgical breach was closed by primary intention, compared with the control group, for which the surgical breach healed by secondary intention. The biomaterial allowed closure of wound by primary intention, reducing the healing time. Minor amputations were performed in nine study group subjects and eight control group subjects. Major amputations (P=0.0019) and re-hospitalization rates (P=0.028) were significantly fewer in the Integra group. Limitations of the study include the small individual population and short-term follow-up. The authors concluded that additional studies are needed with large individual populations and long-term follow-up to validate these findings.

Integra Reinforcement Matrix (Integra LifeSciences, Princeton, NJ) is an acellular porcine dermal matrix proposed for use in the reconstruction of soft tissue deficiencies. Per Lifesciences, the matrix is “intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue, including reinforcement of the rotator cuff, patellar, Achilles, biceps, quadriceps, or other tendons. Integra Reinforcement Matrix is not intended to replace normal body structure or provide full mechanical strength. Sutures used to repair the tear and sutures or bone anchors used to attach the tissue to the bone provide biomechanical strength for the tendon repair.” The Integra Reinforcement Matrix is available in 4×7 cm and 5×10 cm. There is insufficient evidence in the published peer-reviewed literature to support the safety and effectiveness of this matrix.

Membrane Wrap (BioLab Holdings Inc., Mesa, AZ) is a dual-layered dehydrated human amnion membrane allograft composed primarily of a connective tissue matrix. It is proposed to be minimally manipulated, preserving the natural growth factors and cytokines that are present in amniotic tissue. The product is proposed for chronic and postsurgical wound healing including the treatment of nonhealing acute and chronic wounds (diabetic, venous, mixed, venous-arterial, pressure ulcers), complex and/or open surgical wounds and burns, for children and adults. It is available in various sizes (BioLab Holdings, 2025). Membrane Graft is a similar product by BioLab proposed for the same indications (CMS, May 2019). There is insufficient evidence to support the clinical effectiveness of these products. Membrane Graft and Membrane Wrap (BioLab Sciences, Inc.) are human amniotic allograft membranes that are intended to be used to repair tissue deficits and to reduce healing time for chronic wounds and postsurgical wounds; Membrane Wrap-Hydro (BioLab Sciences, Inc.) is a hydrated human amnion membrane that is indicated for chronic and acute wounds. The product serves as a protective covering from the surrounding environment for acute and chronic wounds. Membrane Wrap-Lite (BioLab Sciences, Inc.) is a human amnion single-layer allograft that is indicated for acute and chronic wounds. There are few published studies that address the use of Membrane Graft, Membrane Wrap, Membrane Wrap-Hydro, and Membrane Wrap-Lite. Therefore, it is not possible to determine whether these products have a beneficial effect on health outcomes.

While the published data discuss presence and potential of positive outcomes, they predominately draw from small, retrospective studies or case reports, which are not sufficient reliable evidence to draw definitive conclusions regarding effectiveness of skin substitutes. There is also a scarcity of data comparing skin substitutes with each other or controls. Prospective, randomized, and controlled study designs with sufficient power and appropriate objective clinical outcomes with long-term follow-ups remain warranted.

PROFESSIONAL SOCIETIES/ORGANIZATIONS

In 2016, the American Society of Colon and Rectal Surgeons published clinical practice guidelines for the management of anorectal abscess, fistula-in-ano, and rectovaginal fistula (Vogel et al., 2016). The guidelines state that the fistula plug is a relatively ineffective treatment for fistula-in-ano. The guidelines did not include the use of collagen plug for rectovaginal fistulas owing to the prohibitively poor success of this intervention.

Based on data from a prospective, multicenter registry of 245 individuals who underwent surgical intervention for anal fistula, the New England Regional Society of the American Society of Colon and Rectal Surgeons (Hyman et al., 2009) reported that the best healing rates occurred following fistulotomy (87 percent) and the worst healing rates occurred following anal fistula plug (32 percent) (P=0.001). They stated that RCTs comparing various treatment options for anal fistulas “are clearly needed.”

The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) (Daly et al., 2024) guidelines for hiatal hernia repair are based on a systematic review of the evidence in the published peer-reviewed scientific literature. One objective was to assess the benefits and harms associated with the surgical management options of using mesh versus no mesh. Large hiatal hernias were defined as those measuring more than 2 cm in any direction. The guideline panel deferred making a recommendation on the routine use because the evidence was lacking. They concluded that the use of mesh must be a joint decision between surgeon and individual; large, well-designed RCTs comparing type of mesh used and orientation of the mesh are required to better establish the safety and long-term outcomes of mesh use at the hiatus.

The Society for Vascular Surgery/American Podiatric Medical Association/Society for Vascular Medicine (SVS/APMA/SVM) published a joint evidence-based guideline for the management of individuals with diabetes, including treatment of diabetes-related chronic foot ulcers (Hingorani et al., 2016). These organizations recommended the following:

  • ​Standard wound therapy for diabetic ulcers includes moist dressings, offloading, and debridement.
  • For DFUs that fail to demonstrate improvement (>50 percent wound area reduction) after a minimum of 4 weeks of standard wound therapy, adjunctive wound therapy options include biologics (platelet-derived growth factor, living cellular therapy, extracellular matrix products, or amniotic membrane products). The choice of adjuvant therapy is based on clinical findings, availability of therapy, and cost-effectiveness; there is no recommendation on ordering of therapy choice. Reevaluation of vascular status, infection control, and offloading is recommended to ensure optimization before initiation of adjunctive wound therapy (grade 1B). 
  • Consider living cellular therapy using a bilayered keratinocyte/fibroblast construct or a fibroblast-seeded matrix for treatment of DFUs when the individual is recalcitrant to standard therapy (grade 2B).
  • Consider the use of extracellular matrix products using acellular human dermis or porcine small intestinal submucosal tissue as an adjunctive therapy for DFUs when the individual is recalcitrant to standard therapy (grade 2C).

Wound Healing Society (WHS): The WHS has published updated evidence-based guidelines on the treatment of diabetic ulcers. Regarding the use of skin substitutes, the WHS concluded the following:

  • ​Cellular, bioengineered skin substitutes increase the incidence of healing and decrease the time to heal (level I – unchanged).
  • ADM products have been shown to increase the incidence of healing and decrease the time to heal (level I – unchanged).
  • Human amniotic tissue membranes have been shown to increase the incidence of healing and decrease the time to heal (level I).
  • Synthetic skin equivalents have been shown to increase the incidence of healing and decrease the time to heal (level II).
  • The strength of evidence used in the previous guidelines has been retained:
    • ​Level I: Meta-analysis or at least two RCTs supporting the intervention of the guideline. Another route would be multiple laboratory or animal experiments, with at least two clinical series supporting the laboratory results.
    • Level II: Less than level I, but at least one RCT and at least two significant clinical series or expert opinion papers, with literature reviews supporting the intervention. Experimental evidence that is quite convincing but not yet supported by adequate human experience.
    • Level III: Suggestive data of proof of principle but lacking sufficient data such as meta-analysis, RCT, or multiple clinical series (Lavery et al., 2016; updated 2023). In an evidence-based guideline for venous ulcers, the WHS stated that there is evidence that a bilayered living human skin equivalent, used in conjunction with compression bandaging, increases the incidence and speed of healing for venous ulcers compared with compression and a simple dressing (level I evidence). The WHS recommends adequate wound bed preparation and control of excess bioburden levels prior to application of a biologically active dressing. They also noted that cultured epithelial autografts or allografts have not been demonstrated to improve stable healing of venous ulcers (level I). The WHS also stated that there is level II evidence that a porcine small intestinal submucosal construct may enhance healing of venous ulcers (Marston et al., 2016).
The NICE clinical guideline on diabetic foot problems considers dermal or skin substitutes as an adjunct to standard care when treating DFUs only when healing has not progressed and on the advice of the multidisciplinary foot care service. Their recommendation does not specify which dermal or skin substitutes are considered to be effective (NICE, 2015; updated October 2019).
In 2023, the International Working Group on the Diabetic Foot (IWGDF) updated their evidence-based guidelines  on wound healing interventions to promote healing of foot ulcers in persons with diabetes. This is an update of their 2019 guideline (Hu et al., 2023). All recommendations should be considered adjunctive to best SOC when best SOC alone has failed to heal the ulcers. This should include sharp debridement and basic wound dressings, which according to the IWGDF Practical Guidelines, should be dressings to absorb exudate and maintain a moist wound healing environment. The IWGDF made the following suggestions:

  • Do not use cellular skin substitute products as a routine adjunct therapy to SOC for wound healing in individuals with diabetes-related foot ulcers (conditional; low).
  • Do not use acellular skin substitute products as a routine adjunct therapy to SOC for wound healing in individuals with diabetes-related foot ulcers (conditional; low).
  • Do not use autologous skin graft skin substitute products as an adjunct therapy for wound healing in individuals with diabetes-related foot ulcers (strong; low).
  • With the exception of an autologous leucocyte, platelet, and fibrin patch, do not use autologous platelet therapy (including blood bank–derived platelets) as an adjunct therapy to SOC (conditional; low).
  • Consider the use of an autologous leucocyte, platelet, and fibrin patch for diabetes-related foot ulcers as an adjunctive therapy to SOC where best SOC alone has been ineffective and where the resources and expertise exist for the regular venipuncture required (conditional; moderate).
  • Do not use other cell therapy as an adjunct therapy to SOC for wound healing in people with diabetes-related foot ulcers (conditional; low).
  • Do not use growth factor therapy as an adjunct therapy to SOC for wound healing in people with diabetes-related foot ulcers (conditional; low).
  • Consider the use of placental-derived products as an adjunct therapy to SOC for wound healing in people with diabetes-related foot ulcers in whom SOC alone has failed (conditional; low).

References

Agency for Healthcare Research and Quality (AHRQ). Skin substitutes for treating chronic wounds. [AHRQ Web site]. 10/03/2019. Available at: https://www.ahrq.gov/. Accessed April 3, 2026.

Ahuje NK, Datiashvilli RO. Biobrane in the management of critical microsurgical wounds of the upper extremity. Microsurgery. 2012;32(3):196-200.

Alomairi AA, Alhatlani RA, Alharbi SM, et al. Assessing the application and effectiveness of human amniotic membrane in the management of venous and diabetic ulcers: a systematic review and meta-analysis of randomized controlled trials. Cureus. 2024;16(3):e56659.

Álvaro-Afonso FJ, García-Álvarez Y, Lázaro-Martínez JL, et al. Advances in dermoepidermal skin substitutes for diabetic foot ulcers. Curr Vasc Pharmacol. 2020;18(2):182-192.

Amani H, Dougherty WR, Blome-Eberwein S. Use of Transcyte and dermabrasion to treat burns reduces length of stay in burns of all size and etiology. Burns. 2006;32(7):828-832.

American Burn Association (ABA). Burn incidence and treatment in the US. [ABA Web site]. 2025. Available at: https://www.ameriburn.org/prevention/burn-incidence-and-treatment-in-the-united-states. Accessed April 3, 2026.

American Burn Association (ABA). Surgical management of the burn wound and use of skin substitutes. [Euskal Herriko Unibertsitatea Web site]. 2009. Available at: http://www.oc.lm.ehu.es/Fundamentos/fundamentos/Textos/American Burn Association.pdf. Accessed April 3, 2026.

American Society of Plastic Surgeons (ASPS). Evidence-based Clinical Practice Guideline: Chronic Wounds of the Lower Extremity. May 2007. Available at: http://www.plasticsurgery.org/Documents/medical-professionals/health-policy/evidence-practice/Evidence-based-Clinical-Practice-Guideline-Chronic-Wounds-of-the-Lower-Extremity.pdf. Accessed April 3, 2026.

Ananian CE, Dhillon YS, Van Gils CC, et al. A multicenter, randomized, single-blind trial comparing the efficacy of viable cryopreserved placental membrane to human fibroblast-derived dermal substitute for the treatment of chronic diabetic foot ulcers. Wound Repair Regen. 2018;26(3):274-283.

Baldursson BT, Kjartansson H, Konradsdottir F, et al. Healing rate and autoimmune safety of full-thickness wounds treated with fish skin acellular dermal matrix versus porcine small-intestine submucosa: a noninferiority study. Int J Low Extrem Wounds. 2015;14(1):37-43.

Banta MN, Eaglstein WH, Kirsner RS. Healing of refractory sinus tracts by dermal matrix injection with Cymetra. Dermatol Surg. 2003;29(8):863-866.

Barendse-Hofmann MG, van Doorn LP, Oskam J, Steenvoorde P. Extracellular matrix prevents split-skin grafting in selected cases. J Wound Care. 2007;16(10):455-458.

Barret JP, Dziewulski P, Ramzy PI, et al. Biobrane versus 1 percent silver sulfadiazine in second-degree pediatric burns. Plast Reconstr Surg. 2000;105(1):62-65.

Bascone CM, Deitermann A, Lin SK, et al. Using integra for reconstruction of facial defects after Mohs micrographic surgery. Plast Reconstr Surg Glob Open. 2023;11(12):e5474. 

Bassetto PF, Lopez-Gutierrez PJC, Giunta PR, et al. Integra's legacy unveiled: expert panel recommendations summarizing 25 years of experience in head and neck reconstruction. JPRAS Open. 2025;44:233-245. 

Beale EW, Hoxworth RE, Livingston EH, Trussler AP. The role of biologic mesh in abdominal wall reconstruction: a systematic review of the current literature. Am J Surg. 2012;204(4):510-517. 

Bello YM, Falabella AF, Eaglstein WH. Tissue-engineered skin. Current status in wound healing. Am J Clin Dermatol. 2001;2(5):305-313.

Bianchi C, Cazzell S, Vayser D, et al. A multicentre randomised controlled trial evaluating the efficacy of dehydrated human amnion/chorion membrane (EpiFix (R) ) allograft for the treatment of venous leg ulcers. Int Wound J. 2018;15(1):114-122.

Bianchi C, Tettelbach W, Istwan N, et al. Variations in study outcomes relative to intention-to-treat and per-protocol data analysis techniques in the evaluation of efficacy for treatment of venous leg ulcers with dehydrated human amnion/chorion membrane allograft. Int Wound J. 2019;16(3):761-767.

Biglari B, vd Linden PH, Simon A, et al. Use of Medihoney as a non-surgical therapy for chronic pressure ulcers in patients with spinal cord injury. Spinal Cord. 2012;50(2):165-169.

Bishop JF. Pediatric considerations in the use of Biobrane in burn wound management. J Burn Care Rehabil. 1995;16(3 Pt 1):331-333.

Blot SI, Monstrey SJ, Hoste EA. Carsin H, et al. Cultured epithelial autografts in extensive burn coverage of severely traumatized patients: a five year single-center experience with 30 patients. [Comment on Burns 2000;26:379-387]. Burns. 2001 Jun;27(4):418-419.

Blue Cross and Blue Shield Technology Evaluation Center (TEC). Graftskin for the treatment of skin ulcers. TEC Assessments. 2001;Volume 16:Tab 12.

Bosteels J, Weyers S, D'Hooghe TM, et al. Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility. Cochrane Database Syst Rev. 2017;11(11):CD011110. 

Branski LK, Herndon DN, Pereira C, et al. Longitudinal assessment of Integra in primary burn management: a randomized pediatric clinical trial. Crit Care Med. 2007;35(11):2615-2623.

Brem H, Balledux J, Sukkarieh T, et al. Healing of venous ulcers of long duration with a bilayered living skin substitute: results from a general surgery and dermatology department. Dermatol Surg. 2001;27(11):915-919.

Brem H, Kirsner RS, Falanga V. Protocol for the successful treatment of venous ulcers. Am J Surg. 2004;188(1A Suppl):1-8.

Bren L. Helping wounds heal. US Food and Drug Administration (FDA). FDA Consum. 2002;36(3):23-28.

Breuing KH, Colwell AS. Inferolateral AlloDerm hammock for implant coverage in breast reconstruction. Ann Plast Surg. 2007;59(3):250-255.

Brigido SA. The use of an acellular dermal regenerative tissue matrix in the treatment of lower extremity wounds: a prospective 16-week pilot study. Int Wound J. 2006;3(3):181-187.

Brigido SA, Boc SF, Lopez RC. Effective management of major lower extremity wounds using an acellular regenerative tissue matrix: a pilot study. Orthopedics. 2004;27(1 Suppl):s145-149.

Brigido SA, Schwartz E, McCarroll R, Hardin-Young J. Use of an acellular flowable dermal replacement scaffold on lower extremity sinus tract wounds: a retrospective series. Foot Ankle Spec. 2009;2(2):67-72.

Brown-Etris M, Milne CT, Hodde JP. An extracellular matrix graft (Oasis® wound matrix) for treating full-thickness pressure ulcers: a randomized clinical trial. J Tissue Viability. 2019;28(1):21-26.

Callcut RA, Schurr MJ, Sloan M, Faucher LD. Clinical experience with Alloderm: a one-staged composite dermal/epidermal replacement utilizing processed cadaver dermis and thin autografts. Burns. 2006;32(5):583-588.

Campitiello F, Mancone M, Della Corte A, et al. To evaluate the efficacy of an acellular Flowable matrix in comparison with a wet dressing for the treatment of patients with diabetic foot ulcers: a randomized clinical trial. Updates Surg. 2017;69(4): 523-529.

Carsin H, Ainaud P, Le Bever H, et al. Cultured epithelial autografts in extensive burn coverage of severely traumatized patients: a five year single-center experience with 30 patients. Burns. 2000;26(4):379-387.

Cassidy C, St. Peter SD, Lacey S, et al. Biobrane versus duoderm for the treatment of intermediate thickness burns in children: a prospective, randomized trial. Burns. 2005;31(7):890-893.

Cazzell S. A randomized controlled trial comparing a human acellular dermal matrix versus conventional care for the treatment of venous leg ulcers. Wounds. 2019;31(3):68-74.

Cazzell S, Vayser D, Pham H, et al. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. Wound Repair Regen. 2017;25(3):483-497.

Centers for Medicare and Medicaid Services (CMS). National Coverage Determination (NCD) 270.5: Porcine skin and gradient pressure dressing. [CMS Web site]. Available at: https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=139&NCDver=1. Accessed April 3, 2026.

Chang DW, Sanchez LA, Veith FJ, et al. Can a tissue-engineered skin graft improve healing of lower extremity foot wounds after revascularization? Ann Vasc Surg. 2000;14(1):44-49.

Chen J, Xu J, Wang A, Zheng M. Scaffolds for tendon and ligament repair: review of the efficacy of commercial products. Expert Rev Med Devices. 2009;6(1):61-73.

Cheng A, Saint-Cyr M. Comparison of different ADM materials in breast surgery. Clin Plast Surg. 2012;39(2):167-175.

Cohen IK, Diegelman RF, Yager DR, et al. Wound care and wound healing. In: Schwartz SI, Shires GT, Spencer FC, et al, eds. Principles of Surgery. 7th ed. New York, NY: McGraw-Hill; 1999: 264, 285.

Compton CC. Current concepts in pediatric burn care: the biology of cultured epithelial autografts: an eight-year study in pediatric burn patients. Eur J Pediatr Surg. 1992;2(4):216-222.

Cross W, Kumar A, Chandru Kowdley G. Biological mesh in contaminated fields--overuse without data: a systematic review of their use in abdominal wall reconstruction. Am Surg. 2014;80(1):3-8. Erratum in: Am Surg. 2014;80(5):526. 

Curran MP, Plosker GL. Bilayered bioengineered skin substitute (Apligraf): a review of its use in the treatment of venous leg ulcers and diabetic foot ulcers. BioDrugs. 2002;16(6):439-455.

Daly S, Kumar SS, Collings AT, et al. SAGES guidelines for the surgical treatment of hiatal hernias. Surg Endosc. 2024;38(9):4765-4775.

Dantzer E, Braye FM. Reconstructive surgery using an artificial dermis (Integra): results with 39 grafts. Br J Plast Surg. 2001;54(8):659-664.

Dantzer E, Queruel P, Salinier L, et al. Dermal regeneration template for deep hand burns: clinical utility for both early grafting and reconstructive surgery. Br J Plast Surg. 2003;56(8):764-774.

Dardari D, Piaggesi A, Potier L, et al. Intact Fish Skin Graft to Treat Deep Diabetic Foot Ulcers. NEJM Evid. 2024 Dec;3(12):EVIDoa2400171.

Demling RH. Use of Biobrane in management of scalds. J Burn Care Rehabil. 1995;16(3 Pt 1):329-330.

Demling RH, DeSanti L. Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns. 1999;25(3):256-261.

Dessy LA, Mazzocchi M, Rizzo MI, et al. Scalp reconstruction using dermal induction template: state of the art and personal experience. In Vivo. 2013;27(1):153-158.

Dhanraj P. A clinical study comparing Helicoll with Scarlet Red and OpSite in the treatment of split thickness skin graft donor sites--a randomized controlled trial. Indian J Surg. 2015;77(Suppl 2):385-392. 

DiDomenico LA, Landsman AR, Emch KJ, Landsman A. A prospective comparison of diabetic foot ulcers treated with either a cryopreserved skin allograft or a bioengineered skin substitute. Wounds. 2011;23(7):184-189.

DiDomenico LA, Orgill DP, Galiano RD, et al. Aseptically processed placental membrane improves healing of diabetic foot ulcerations: prospective, randomized clinical trial. Plast Reconstr Surg Glob Open. 2016;4(10):e1095. 

DiDomenico LA, Orgill DP, Galiano RD, et al. Use of an aseptically processed, dehydrated human amnion and chorion membrane improves likelihood and rate of healing in chronic diabetic foot ulcers: a prospective, randomised, multi-centre clinical trial in 80 patients. Int Wound J. 2018;15(6):950-957. 

Driver VR, Lavery LA, Reyzelman AM, et al. A clinical trial of Integra Template for diabetic foot ulcer treatment. Wound Repair Regen. 2015;23(6):891-900.

Duteille F, Perrot P. Management of 2nd-degree facial burns using the Versajet® hydrosurgery system and xenograft: a prospective evaluation of 20 cases. Burns. 2012;38(5):724-729.

Eaglstein WH, Alvarez OM, Auletta M, et al. Acute excisional wounds treated with a tissue-engineered skin (Apligraf). Dermatol Surg. 1999;25(3):195-201.

Ehrenreich M, Ruszczak Z. Update on tissue-engineered biological dressings. Tissue Eng. 2006;12(9):2407-2424.

Eisenberg M, Llewelyn D. Surgical management of hands in children with recessive dystrophic epidermolysis bullosa: use of allogeneic composite cultured skin grafts. Br J Plast Surg. 1998;51(8):608-613.

Ellis CV, Kulber DA. Acellular dermal matrices in hand reconstruction. Plast Reconstr Surg. 2012;130(5 Suppl 2):256S-269S.

Esposito F, Angileri FF, Kruse P, et al. Fibrin sealants in dura sealing: a systematic literature review. PLoS One. 2016;11(4):e0151533.

Falabella AF, Valencia IC, Eaglstein WH, Schachner LA. Tissue-engineered skin (Apligraf) in the healing of patients with epidermolysis bullosa wounds. Arch Dermatol. 2000;136(10):1225-1230.

Falanga V, Margolis D, Alvarez O, et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human Skin Equivalent Investigators Group. Arch Dermatol. 1998;134(3):293-300.

Falanga V, Sabolinski M. A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen. 1999;7(4):201-207.

Felcht M, Koenen W, Sassmann G, et al. Two-stage reconstruction of head and neck defects after tumor resection with a dermal regeneration template. J Cutan Med Surg. 2011;15(5):259-265.

Felder JM 3rd, Goyal SS, Attinger CE. A systematic review of skin substitutes for foot ulcers. Plast Reconstr Surg. 2012;130(1):145-164.

Ferzoco SJ. A systematic review of outcomes following repair of complex ventral incisional hernias with biologic mesh. Int Surg. 2013;98(4):399-408.

Fette A. Integra artificial skin in use for full-thickness burn surgery: benefits or harms on patient outcome. Technol Health Care. 2005;13(6):463-468.

Fetterolf DE, Snyder RJ. Scientific and clinical support for the use of dehydrated amniotic membrane in wound management. Wounds. 2012;24(10):299-307.

Figus A, Leon-Villapalos J, Philp B, Dziewulski P. Severe multiple extensive postburn contractures: a simultaneous approach with total scar tissue excision and resurfacing with dermal regeneration template. J Burn Care Res. 2007;28(6):913-917.

Fine JD. Skin bioequivalents and their role in the treatment of inherited epidermolysis bullosa. Arch Dermatol. 2000;136(10):1259-1260.

Fivenson DP, Scherschun L. Clinical and economic impact of Apligraf for the treatment of nonhealing venous leg ulcers. Int J Dermatol. 2003;42(12):960-965.

Fivenson DP, Scherschun L, Choucair M, et al. Graftskin therapy in epidermolysis bullosa. J Am Acad Dermatol. 2003;48(6):886-892.

Fivenson DP, Scherschun L, Cohen LV. Apligraf in the treatment of severe mitten deformity associated with recessive dystrophic epidermolysis bullosa. Plast Reconstr Surg. 2003;112(2):584-588.

Forbes J, Fetterolf DE. Dehydrated amniotic membrane allografts for the treatment of chronic wounds: a case series. J Wound Care. 2012;21(6):290-296.

Fraccalvieri M, Pristera G, Zingarelli E, et al. Treatment of chronic heel osteomyelitis in vasculopathic patients. Can the combined use of Integra®, skin graft and negative pressure wound therapy be considered a valid therapeutic approach after partial tangential calcanectomy? Int Wound J. 2012;9(2):214-220.

Frame JD, Still J, Lakhel-LeCoadou A, et al. Use of dermal regeneration template in contracture release procedures: a multicenter evaluation. Plast Reconstr Surg. 2004;113(5):1330-1338.

Frykberg RG, Cazzell SM, Arroyo-Rivera J, et al. Evaluation of tissue engineering products for the management of neuropathic diabetic foot ulcers: an interim analysis. J Wound Care. 2016;25(Sup7):S18-S25.

Frykberg RG, Gibbons GW, Walters JL, et al. A prospective, multicentre, open-label, single-arm clinical trial for treatment of chronic complex diabetic foot wounds with exposed tendon and/or bone: positive clinical outcomes of viable cryopreserved human placental membrane. Int Wound J. 2017;14(3):569-577.

Frykberg RG, Marston WA, Cardinal M. The incidence of lower-extremity amputation and bone resection in diabetic foot ulcer patients treated with a human fibroblast-derived dermal substitute. Adv Skin Wound Care. 2015;28(1):17-20.

Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg. 2006;45(5 Suppl):S1-S66.

Gallico GG 3rd, O'Connor NE, Compton CC, et al. Cultured epithelial autografts for giant congenital nevi. Plast Reconstr Surg. 1989;84(1):1-9.

Garramone CE, Lam B. Use of AlloDerm in primary nipple reconstruction to improve long-term nipple projection. Plast Reconstr Surg. 2007;119(6):1663-1668.

Gentzkow GD, Iwasaki SD, Hershon KS, et al. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care. 1996;19(4):350-354.

Gerding RL, Emerman CL, Effron D, et al. Outpatient management of partial-thickness burns: Biobrane versus 1% silver sulfadiazine. Ann Emerg Med. 1990;19(2):121-124.

Gonzalez SR, Wolter KG, Yuen JC. Infectious complications associated with the use of Integra: a systematic review of the literature. Plast Reconstr Surg Glob Open. 2020;8(7):e2869.

Gordon AJ, Alfonso AR, Nicholson J, Chiu ES. Evidence for healing diabetic foot ulcers with biologic skin substitutes: a systematic review and meta-analysis. Ann Plast Surg. 2019;83(4S Suppl 1):S31-S44.

Gore DC. Utility of acellular allograft dermis in the care of elderly burn patients. J Surg Res. 2005;125(1):37-41.

Graham GP, Helmer SD, Haan JM, Khandelwal A. The use of Integra® Dermal Regeneration Template in the reconstruction of traumatic degloving injuries. J Burn Care Res. 2013;34(2):261-266.

Grande DJ. Skin grafting. [Medscape Web site]. 07/27/2023. Available at: https://emedicine.medscape.com/article/1129479-overview. Accessed April 3, 2026.

Gravante G, Delogu D, Giordan N, et al. The use of Hyalomatrix PA in the treatment of deep partial-thickness burns. J Burn Care Res. 2007;28(2):269-274.

Gravante G, Sorge R, Merone A, et al. Hyalomatrix PA in burn care practice: results from a national retrospective survey, 2005-2006. Ann Plast Surg.2010;64(1):69-79.

Gurtner GC, Garcia AD, Bakewell K, Alarcon JB. A retrospective matched-cohort study of 3994 lower extremity wounds of multiple etiologies across 644 institutions comparing a bioactive human skin allograft, TheraSkin, plus standard of care, to standard of care alone. Int Wound J. 2020;17(1):55-64.

Guo X, Mu D, Gao F. Efficacy and safety of acellular dermal matrix in diabetic foot ulcer treatment: a systematic review and meta-analysis. Int J Surg. 2017;40:1-7.

Haith LR Jr, Patton ML, Goldman WT. Cultured epidermal autograft and the treatment of the massive burn injury. J Burn Care Rehabil. 1992;13(1):142-146.

Hankin CS, Knispel J, Lopes M, et al. Clinical and cost efficacy of advanced wound care matrices for venous ulcers. J Manag Care Pharm. 2012;18(5):375-384.

Harding K, Cutting K, Price P. The cost-effectiveness of wound management protocols of care. Br J Nurs. 2000;9(19 Suppl):S6-S24.

Harding K, Sumner M, Cardinal M. A prospective, multicentre, randomised controlled study of human fibroblast-derived dermal substitute (Dermagraft) in patients with venous leg ulcers. Int Wound J. 2013;10(2):132-137.

Hayes, Inc. Biosynthetic tissue-engineered skin substitutes for wound healing. Lansdale, PA: Hayes, Inc.;[via subscription only]. 01/14/2014 (archived).

Hayes, Inc. Skin substitutes for wound healing. Lansdale, PA: Hayes, Inc.;[via subscription only]. 02/09/2007 (updated from 02/2004; archived).

Hayn E. Successful treatment of complex traumatic and surgical wounds with a foetal bovine dermal matrix. Int Wound J. 2014;11(6):675-680.

Healy CM, Boorman JG. Comparison of E-Z Derm and Jelonet dressings for partial skin thickness burns. Burns Incl Therm Inj. 1989;15(1):52-54.

Heimbach D, Luterman A, Burke J, et al. Artificial dermis for major burns. A multi-center randomized clinical trial. Ann Surg. 1988;208(3):313-320.

Heimbach DM, Warden GD, Luterman A, et al. Multicenter postapproval clinical trial of Integra dermal regeneration template for burn treatment. J Burn Care Rehabil. 2003;24(1):42-48.

Heitland A, Piatkowski A, Noah EM, Pallua N. Update on the use of collagen/glycosaminoglycate skin substitute – six years of experiences with artificial skin in 15 German burn centers. Burns. 2004;30(5):471-475.

Helgeson MD, Potter BK, Evans KN, Shawen SB. Bioartificial dermal substitute: a preliminary report on its use for the management of complex combat-related soft tissue wounds. J Orthop Trauma. 2007;21(6):394-399.

Hickerson WL, Compton C, Fletchall S, Smith LR. Cultured epidermal autografts and allodermis combination for permanent burn wound coverage. Burns. 1994;20 Suppl 1:S52-S55.

Hicks KE, Huynh MN, Jeschke M, Malic C. Dermal regenerative matrix use in burn patients: a systematic review. J Plast Reconstr Aesthet Surg. 2019;72(11):1741-1751.

Hingorani A, LaMuraglia GM, Henke P, et al. The management of diabetic foot: a clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg. 2016;63(2 Suppl):3S-21S.

Ho T, Couch M, Carson K, et al. Radial forearm free flap donor site outcomes comparison by closure methods. Otolaryngol Head Neck Surg. 2006;134(2):309-315.

Homicz MR, Watson D. Review of injectable materials for soft tissue augmentation. Facial Plast Surg. 2004;20(1):21-29.

Horch RE, Kopp J, Kneser U, et al. Tissue engineering of cultured skin substitutes. J Cell Mol Med. 2005;9(3):592-608.

Hsu, GS. Utilizing dehydrated human amnion/chorion membrane allograft in transcanal tympanoplasty. Otolaryngology. 2014;4(2):161.

Hu X, Zhang Y, Chen Y, Zhang YP. Validation and application of the 2019 International Working Group on the Diabetic Foot risk stratification for diabetic foot in Chinese patients. J Diabetes Investig. 2023;14(7):893-901.

Hubik DJ, Wasiak J, Paul E, Cleland H. Biobrane: a retrospective analysis of outcomes at a specialist adult burns centre. Burns. 2011;37(4):594-600.

Hui A, Hong P, Bezuhly M. Use of acellular dermal matrices in laryngotracheal and pharyngeal reconstruction: systematic review. J Laryngol Otol. 2017;131(7):585-592.


Hyman NH. Managing anastomotic leaks from intestinal anastomoses. Surgeon. 2009;7(1):31-35. 


Iorio ML, Goldstein J, Adams M, et al. Functional limb salvage in the diabetic patient: the use of a collagen bilayer matrix and risk factors for amputation. Plast Reconstr Surg. 2011;127(1):260-267.

Iorio ML, Shuck J, Attinger CE. Wound healing in the upper and lower extremities: a systematic review on the use of acellular dermal matrices. Plast Reconstr Surg. 2012;130 (5 Suppl 2) 232S-241S.

Janis JE, O'Neill AC, Ahmad J, et al. Acellular dermal matrices in abdominal wall reconstruction: a systematic review of the current evidence. Plast Reconstr Surg. 2012;130(5 Suppl 2):183S-193S. 

Jones JE, Nelson EA, Al-Hity A. Skin grafting for venous leg ulcers. Cochrane Database Syst Rev. 2013;(1):CD001737.

Kahn SA, Beers RJ, Lentz CW. Use of acellular dermal replacement in reconstruction of nonhealing lower extremity wounds. J Burn Care Res. 2011;32(1):124-128.

Karpenko AN, Dworkin JP, Meleca RJ, Stachler RJ. Cymetra injection for unilateral vocal fold paralysis. Ann Otol Rhinol Laryngol. 2003;112(11):927-934.

Karr JC. Retrospective comparison of diabetic foot ulcer and venous stasis ulcer healing outcome between a dermal repair scaffold (PriMatrix) and a bilayered living cell therapy (Apligraf). Adv Skin Wound Care. 2011;24(3):119-125.

Kashefsky H, Marston W. Total contact casting combined with human fibroblast-derived dermal tissue in 15 DFU patients. J Wound Care. 2012;21(5):236-243.

Kavros SJ. Acellular fetal bovine dermal matrix for treatment of chronic ulcerations of the midfoot associated with Charcot neuroarthropathy. Foot Ankle Spec. 2012;5(4):230-234.

Kavros SJ, Dutra T, Gonzalez-Cruz R, et al. The use of PriMatrix, a fetal bovine acellular dermal matrix, in healing chronic diabetic foot ulcers: a prospective multicenter study. Adv Skin Wound Care. 2014;27(8):356-362.

Kelechi TJ, Mueller M, Hankin CS, et al. A randomized, investigator-blinded, controlled pilot study to evaluate the safety and efficacy of a poly-N-acetyl glucosamine-derived membrane material in patients with venous leg ulcers. J Am Acad Dermatol. 2012;66(6):e209-e215.

Kim PJ, Dybowski KS, Steinberg JS. A closer look at bioengineered alternative tissues. Podiatry Today (serial online). [Podiatry Today Web site]. July 2006. Available at: http://www.podiatrytoday.com/article/5820. Accessed April 3, 2026.

Kinaci A, Algra A, Heuts S, et al. Effectiveness of dural sealants in prevention of cerebrospinal fluid leakage after craniotomy: a systematic review. World Neurosurg. 2018;118:368-376.e1.

Kirsner RS, Warriner R, Michela M, et al. Advanced biological therapies for diabetic foot ulcers. Arch Dermatol. 2010;146(8):857-862.

Kissane NA, Itani KMF. A decade of ventral incisional hernia repairs with biologic acellular dermal matrix: what have we learned? Plast Reconstr Surg. 2012;130(5 Suppl 2):194S-202S. Erratum in: Plast Reconstr Surg. 2013;131(2):427-428. 

Koob TJ, Rennert R, Zabek N, et al. Biological properties of dehydrated human amnion/chorion composite graft: implications for chronic wound healing. Int Wound J. 2013;10(5):493-500.

Kumar RJ, Kimble RM, Boots R, Pegg SP. Treatment of partial-thickness burns: a prospective, randomized trial using TransCyte. ANZ J Surg. 2004;74(8):622-626.

Lagus H, Sarlomo-Rikala M, Bohling T, Vuola J. Prospective study on burns treated with Integra®, a cellulose sponge and split thickness skin graft: comparative clinical and histological study--randomized controlled trial. Burns. 2013;39(8):1577-1587.

Lal S, Barrow RE, Wolf SE, et al. Biobrane improves wound healing in burned children without increased risk of infection. Shock. 2000;14(3):314-319.

Landsman AS, Cook J, Cook E, et al. A retrospective clinical study of 188 consecutive patients to examine the effectiveness of a biologically active cryopreserved human skin allograft (TheraSkin®) on the treatment of diabetic foot ulcers and venous leg ulcers. Foot Ankle Spec. 2011;4(1):29-41.

Lang EM, Eiberg CA, Brandis M, Stark GB. Biobrane in the treatment of burn and scald injuries in children. Ann Plast Surg. 2005;55(5):485-489.

Lavery LA, Suludere MA, Attinger CE, et al. WHS (Wound Healing Society) guidelines update: diabetic foot ulcer treatment guidelines. Wound Repair Regen. 2024;32(1):34-46.

Lavery LA, Fulmer J, Shebetka KA, et al. The efficacy and safety of Grafix® for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial. Int Wound J. 2014;11(5):554-560.

Lavery LA, Murdoch DP, Kim PJ, et al. Negative pressure wound therapy with low pressure and gauze dressings to treat diabetic foot wounds. J Diabetes Sci Technol. 2014;8(2):346-349. 

Lazic T, Falanga V. Bioengineered skin constructs and their use in wound healing. Plast Reconstr Surg. 2011;127Suppl 1:75S-90S.

Lecheminant J, Field C. Porcine urinary bladder matrix: a retrospective study and establishment of protocol. J Wound Care. 2012;21(10):478-482.

Lee LF, Porch JV, Spenler W, Garner WL. Integra in lower extremity reconstruction after burn injury. Plast Reconstr Surg. 2008;121(4):1256-1262.

Li W, Dasgeb B, Phillips T, et al. Wound-healing perspectives. Dermatol Clin. 2005;23(2):181-192.

Limat A, French LE, Blal L, et al. Organotypic cultures of autologous hair follicle keratinocytes for the treatment of recurrent leg ulcers. J Am Acad Dermatol. 2003;48(2):207-214.

Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012;54(12):e132-e173.

Lobmann R, Pittasch D, Mühlen I, Lehnert H. Autologous human keratinocytes cultured on membranes composed of benzyl ester of hyaluronic acid for grafting in nonhealing diabetic foot lesions: a pilot study. J Diabetes Complications. 2003;17(4):199-204.

Locurcio LL, Breen M, Haq J. Can a single-stage approach using a dermal regeneration template lead to satisfactory scalp defect reconstruction after skin cancer excision? J Oral Maxillofac Surg. 2024;82(3):341-346.

Lukish JR, Eichelberger MR, Newman KD, et al. The use of bioactive skin substitute decreases length of stay for pediatric burn patients. J Pediatr Surg. 2001;36(8):1118-1121.

Lullove E. Acellular fetal bovine dermal matrix in the treatment of nonhealing wounds in patients with complex comorbidities. J Am Podiatr Med Assoc. 2012;102(3):233-239.

Lullove EJ, Liden B, McEneaney P, et al. Evaluating the effect of omega-3-rich fish skin in the treatment of chronic, nonresponsive diabetic foot ulcers: penultimate analysis of a multicenter, prospective, randomized controlled trial. Wounds. 2022 Apr;34(4):E34-E36.

Lullove EJ, Liden B, Winters C, et al. A Multicenter, Blinded, Randomized Controlled Clinical Trial Evaluating the Effect of Omega-3-Rich Fish Skin in the Treatment of Chronic, Nonresponsive Diabetic Foot Ulcers. Wounds. 2021 Jul;33(7):169-177.

Marinkovich MP. Epidermolysis bullosa. [eMedicine Web site]. 09/25/2025. Available at: http://www.emedicine.com/derm/topic124.htm. Accessed April 3, 2026.

Marston WA; Dermagraft Diabetic Foot Ulcer Study Group. Risk factors associated with healing chronic diabetic foot ulcers: the importance of hyperglycemia. Ostomy Wound Manage. 2006;52(3):26-32.

Marston WA, Hanft J, Norwood P, et al. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care. 2003;26(6):1701-1705.

Marston W, Tang J, Kirsner RS, Ennis W. Wound Healing Society 2015 update on guidelines for venous ulcers. Wound Repair Regen. 2016;24(1):136-144.

Martin BR, Sangalang M, Wu S, Armstrong DG. Outcomes of allogenic acellular matrix therapy in treatment of diabetic foot wounds: an initial experience. Int Wound J. 2005;2(2):161-165.

Martinson M, Martinson N. A comparative analysis of skin substitutes used in the management of diabetic foot ulcers. J Wound Care. 2016;25(Sup10):S8-S17.

Maus JC, Hemal K, Khan M, et al. Dermal regeneration template and staged skin grafting for extirpative scalp wound reconstruction: a 14-year experience. Otolaryngol Head Neck Surg. 2021;165(2):275-281.

McAree KG, Klein RL, Boeckman CR. The use of cultured epithelial autografts in the wound care of severely burned patients. J Pediatr Surg. 1993;28(2):166-168.

McNamara SA, Hirt PA, Weigelt MA, et al. Traditional and advanced therapeutic modalities for wounds in the paediatric population: an evidence-based review. J Wound Care. 2020;29(6):321-334.

Milstein CF, Akst LM, Hicks MD, et al. Long-term effects of micronized Alloderm injection for unilateral vocal fold paralysis. Laryngoscope. 2005;115(9):1691-1696.

Mogedas-Vegara A, Agut-Busquet E, Yébenes Marsal M, et al. Integra as firstline treatment for scalp reconstruction in elderly patients. J Oral Maxillofac Surg. 2021;79(12):2593-2602.

Moiemen NS, Staiano JJ, Ojeh NO, et al. Reconstructive surgery with a dermal regeneration template: clinical and histologic study. Plast Reconstr Surg. 2001;108(1):93-103.

Moiemen NS, Vlachou E, Staiano JJ, et al. Reconstructive surgery with Integra dermal regeneration template: histologic study, clinical evaluation, and current practice. Plast Reconstr Surg. 2006;117(7Suppl):160S-174S.

Moonis G, Dyce O, Loevner LA, Mirza N. Magnetic resonance imaging of micronized dermal graft in the larynx. Ann Otol Rhinol Laryngol. 2005;114(8):593-598.

Mostow EN, Haraway GD, Dalsing M, et al. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J Vasc Surg. 2005;41(5):837-843.

Muangman P, Deubner H, Honari S, et al. Correlation of clinical outcome of integra application with microbiologic and pathological biopsies. J Trauma. 2006;61(5):1212-1217.

Munster AM. Cultured skin for massive burns. A prospective, controlled trial. Ann Surg. 1996;224(3):372-375; discussion 375-377.

Munster AM, Smith-Meek M, Shalom A. Acellular allograft dermal matrix: immediate or delayed epidermal coverage? Burns. 2001;27(2):150-153.

Narayan N, Nareddula U, Nanjundaiah RK, Manakchand KK. Clinical and histopathological outcomes of high-purity type I collagen in chronic wounds: a systematic review of four randomized controlled trials. Cureus. 2026;18(1):e100717.

Nasseri Y, Cassella L, Berns M, et al. The anal fistula plug in Crohn's disease patients with fistula-in-ano: a systematic review. Colorectal Dis. 2016;18(4):351-356.

National Institute for Health and Care Excellence (NICE). NICE guideline (NG19): Diabetic foot problems: prevention and management [NICE Web site]. 10/11/2019. Available at: https://www.nice.org.uk/guidance/ng19/evidence. Accessed April 3, 2026.

Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. Adv Skin Wound Care. 2005;18(5 Pt 1):258-266.

Noordenbos J, Doré C, Hansbrough JF. Safety and efficacy of TransCyte for the treatment of partial-thickness burns. J Burn Care Rehabil. 1999;20(4):275-281.

Novitas Solutions, Inc. Humanitarian device exemption. [Novitas Web site]. 02/04/2026. Available at: https://www.novitas-solutions.com/webcenter/portal/MedicareJL/pagebyid?contentId=00080348. Accessed April 3, 2026.

Novitas Solutions, Inc. Local Coverage Article (LCA) A54117: Billing and Coding: Application of bioengineered skin substitutes to lower extremity chronic non-healing wounds. [Novitas Web site] Original: 10/01/2015 (Revised 01/01/2026). Available at: https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=54117&ver=88&keyword=Billing and Coding: Application of Bioengineered Skin Substitutes to Lower&keywordType=starts&areaId=all&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=1. Accessed April 3, 2026.

Novitas Solutions, Inc. Local Coverage Determination (LCD) 35041: Application of bioengineered skin substitutes to lower extremity chronic non-healing wounds. [Novitas Web site]. Original: 10/01/2015 (Revised 09/26/2019). Available at: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=35041&ver=113. Accessed April 3, 2026.

O'Donnell TF, Lau J. A systematic review of randomized controlled trials of wound dressings for chronic venous ulcer. J Vasc Surg. 2006;44(5):1118-1125.

Oh SJ, Kim Y. Combined AlloDerm® and thin skin grafting for the treatment of postburn dyspigmented scar contracture of the upper extremity. J Plast Reconstr Aesthet Surg. 2011;64(2):229-233.

Omar AA, Mavor AID, Jones AM, Homer-Vanniasinkam S. Treatment of venous leg ulcers with Dermagraft. Eur J Vasc Endovasc Surg. 2004;27(6):666-672.

O'Meara S, Cullum N, Nelson EA, Dumville JC. Compression for venous leg ulcers. Cochrane Database Syst Rev. 2012;11:CD000265.

O'Riordan JM, Datta I, Johnston C, Baxter NN. A systematic review of the anal fistula plug for patients with Crohn's and non-Crohn's related fistula-in-ano. Dis Colon Rectum. 2012;55(3):351-358.


Othman S, Messa CA 4th, Elfanagely O, et al. Sticking to what matters: a matched comparative study of fibrin glue and mechanical fixation for split-thickness skin grafts in the lower extremity. Int J Low Extrem Wounds. 2024;23(2):231-237.


Ou LF, Lee SY, Chen YC, et al. Use of Biobrane in pediatric scald burns – experience in 106 children. Burns. 1998;24(1):49-53.

Ozerdem OR, Wolfe SA, Marshall D. Use of skin substitutes in pediatric patients. J Craniofac Surg. 2003;14(4):517-520.

Paddle-Ledinek JE, Cruickshank DG, Masterton JP. Skin replacement by cultured keratinocyte grafts: an Australian experience. Burns. 1997;23(3):204-211.

Patel VR, Samavedi S, Bates AS, et al. Dehydrated human amnion/chorion membrane allograft nerve wrap around the prostatic neurovascular bundle accelerates early return to continence and potency following robot-assisted radical prostatectomy: propensity score-matched analysis. Eur Urol. 2015;67(6):977-980.

Paquette D, Falanga V. Leg ulcers. Clin Geriatr Med. 2002;18(1):77-88.

Pearl AW, Woo P, Ostrowski R, et al. A preliminary report on micronized AlloDerm injection laryngoplasty. Laryngoscope. 2002;112(6):990-996.

Peck MD, Kessler M, Meyer AA, Bonham Morris PA. A trial of the effectiveness of artificial dermis in the treatment of patients with burns greater than 45% total body surface area. J Trauma. 2002;52(5):971-978.

Phillips LG, Robson MC, Smith DJ, et al. Uses and abuses of a biosynthetic dressing for partial skin thickness burns. Burns. 1989;15(4):254-256.

Preminger BA, McCarthy CM, Hu QY, et al. The influence of AlloDerm on expander dynamics and complications in the setting of immediate tissue expander/implant reconstruction: a matched-cohort study. Ann Plast Surg. 2008;60(5):510-513.

Purdue GF, Hunt JL, Still JM Jr, et al. A multicenter clinical trial of a biosynthetic skin replacement, Dermagraft-TC, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. J Burn Care Rehabil. 1997;18(1 Pt 1):52-57.

Putland M, Snelling CF, Macdonald I, Tron VA. Histologic comparison of cultured epithelial autograft and meshed expanded split-thickness skin graft. J Burn Care Rehabil. 1995;16(6):627-640.

Rahmanian-Schwarz A, Beiderwieden A, Willkomm LM, et al. A clinical evaluation of Biobrane® and Suprathel® in acute burns and reconstructive surgery. Burns. 2011;37(8):1343-1348.

Reece MK, Walker H, Benintendi I, et al. Delayed skin grafting protocol following Integra™ application for non-radiated scalp reconstruction for decreased wound depth and improved contour. Head Neck. 2023;45(11):2967-2974. 

Remacle M, Lawson G. Results with collagen injection into the vocal folds for medialization. Curr Opin Otolaryngol Head and Neck Surg. 2007;15(3):148-152.

Remacle M, Lawson G, Jamart J, Delos M. Treatment of vocal fold immobility by injectable homologous collagen: short term results. Eur Arch Otorhinolaryngol. 2006;263(3):205-209.

Renner R, Harth W, Simon JC. Transplantation of chronic wounds with epidermal sheets derived from autologous hair follicles – the Leipzig experience. Int Wound J. 2009;6(3):226-232.

Reyzelman A, Crews RT, Moore JC, et al. Clinical effectiveness of an acellular dermal regenerative tissue matrix compared to standard wound management in healing diabetic foot ulcers: a prospective, randomised multicentre study. Int Wound J. 2009;6(3):196-208.

Reyzelman AM, Bazarov I. Human acellular dermal wound matrix for treatment of DFU: literature review and analysis. J Wound Care. 2015;24(3):128-134.

Riboh JC, Saltzman BM, Yanke AB, Cole BJ. Human amniotic membrane-derived products in sports medicine: basic science, early results, and potential clinical applications. Am J Sports Med. 2016;44(9):2425-2434.

Romanelli M, Dini V, Bertone MS. Randomized comparison of OASIS wound matrix versus moist wound dressing in the treatment of difficult-to-heal wounds of mixed arterial/venous etiology. Adv Skin Wound Care. 2010;23(1):34-38.

Romanelli M, Dini V, Bertone M, et al. OASIS wound matrix versus Hyaloskin in the treatment of difficult-to-heal wounds of mixed arterial/venous aetiology. Int Wound J. 2007;4(1):3-7.

Ryan CM, Schoenfeld DA, Malloy M, et al. Use of Integra artificial skin is associated with decreased length of stay for severely injured adult burn survivors. J Burn Care Rehabil. 2002;23(5):311-317.

Sabolinski ML, Alvarez O, Auletta M, et al. Cultured skin as a “smart material" for healing wounds: experience in venous ulcers. Biomaterials. 1996;17(3):311-320.

Saffle JR. Closure of the excised burn wound: temporary skin substitutes. Clin Plast Surg. 2009;36(4):627-641.

Salvatore L, Kodra C, Natali ML, et al. Clinical efficacy of collagen‐based dressings in wound management: a focus on their interactive role in wound healing. Biomed Eng Commun. 2026;5(5):30.

Salzberg CA. Nonexpansive immediate breast reconstruction using human acellular tissue matrix graft (AlloDerm). Ann Plast Surg. 2006;57(1):1-5.

Sanders L, Landsman AS, Landsman A, et al. A prospective, multicenter, randomized, controlled clinical trial comparing a bioengineered skin substitute to a human skin allograft. Ostomy Wound Manage. 2014;60(9):26-38.

Santema TB, Poyck PPC, Ubbink DT. Skin grafting and tissue replacement for treating foot ulcers in people with diabetes. Cochrane Database Syst Rev. 2016;2(2): CD011255.

Schachner L, Feiner A, Camisulli S. Epidermolysis bullosa: management principles for the neonate, infant, and young child. Dermatol Nurs. 2005;17(1):56-59.

Sclafani AP, Romo T 3rd, Jacono AA. Rejuvenation of the aging lip with an injectable acellular dermal graft (Cymetra). Arch Facial Plast Surg. 2002;4(4):252-257.

Serena TE, Carter MJ, Le LT, et al; EpiFix VLU Study Group. A multi-center, randomized, controlled clinical trial evaluating the use of dehydrated human amnion/chorion membrane allografts and multilayer compression therapy vs. multilayer compression therapy alone in the treatment of venous leg ulcers. Wound Repair Regen. 2014;22(6):688-693.

Serena TE, Orgill DP, Armstrong DG, et al. A multicenter, randomized, controlled, clinical trial evaluating dehydrated human amniotic membrane in the treatment of venous leg ulcers. Plast Reconstr Surg. 2022;150(5):1128-1136

Serena TE, Yaakov R, Moore S, et al. A randomized controlled clinical trial of a hypothermically stored amniotic membrane for use in diabetic foot ulcers. J Comp Eff Res. 2020;9(1):23-34.

Shah AP. Using amniotic membrane allografts in the treatment of neuropathic foot ulcers. J Am Podiatr Med Assoc. 2014;104(2):198-202.

Shaharudin A, Aziz Z. Effectiveness of hyaluronic acid and its derivatives on chronic wounds: a systematic review. J Wound Care. 2016;25(10):585-592. 

Sheikh ES, Sheikh ES, Fetterolf DE. Use of dehydrated human amniotic membrane allografts to promote healing in patients with refractory non-healing wounds. Int Wound J. 2014;11(6):711-717.

Sheridan RL, Choucair R, Donelan M, et al. Acellular allodermis in burns surgery: 1-year results of a pilot trial. J Burn Care Rehabil. 1998;19(6):528-530.

Sheridan RL, Morgan JR, Cusick JL, et al. Initial experience with a composite autologous skin substitute. Burns. 2001;27(5):421-424.

Shores JT, Gabriel A, Gupta S. Skin substitutes and alternatives: a review. Adv Skin Wound Care. 2007;20(9 Pt 1):493-508.

Shores JT, Hiersche M, Gabriel A, Supta S. Tendon coverage using an artificial skin substitute. J Plast Reconstr Aesthet Surg. 2012;65(11):1544-1550.

Sibbald RG, Zuker R, Coutts P, et al. Using a dermal skin substitute in the treatment of chronic wounds secondary to recessive dystrophic epidermolysis bullosa: a case series. Ostomy Wound Manage. 2005;51(11):22-46.

Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999;341(10):738-746.

Sinha UK, Shih C, Chang K, Rice DH. Use of AlloDerm for coverage of radial forearm free flap donor site. Laryngoscope. 2002;112(2):230-234.

Smart NJ, Bloor S. Durability of biologic implants for use in hernia repair: a review. Surg Innov. 2012;19(3):221-229. 

Smiell JM, Treadwell T, Hahn HD, Hermans MH. Real-world experience with a decellularized dehydrated human amniotic membrane allograft. Wounds. 2015;27(6):158-169.

Snyder RJ, Shimozaki K, Tallis A, et al. A prospective, randomized, multicenter, controlled evaluation of the use of dehydrated amniotic membrane allograft compared to standard of care for the closure of chronic diabetic foot ulcer. Wounds. 2016;28(3):70-77.

Steinberg JS, Edmonds M, Hurley DP Jr, King WN. Confirmatory data from EU study supports Apligraf for the treatment of neuropathic diabetic foot ulcers. J Am Podiatr Med Assoc. 2010;100(1):73-77.

Stiefel D, Schiestl C, Meuli M. Integra Artificial Skin for burn scar revision in adolescents and children. Burns. 2010;36(1):114-120.

Still J, Glat P, Silverstein P, et al. The use of a collagen sponge/living cell composite material to treat donor sites in burn patients. Burns. 2003;29(8):837-841.

Still JM Jr, Orlet HK, Law EJ. Use of cultured epidermal autografts in the treatment of large burns. Burns. 1994;20(6):539-541.

Sood R, Roggy D, Zieger M, et al. Cultured epithelial autografts for coverage of large burn wounds in eighty-eight patients: the Indiana University experience. J Burn Care Res. 2010;31(4):559-568.

Subach BR, Copay AG. The use of a dehydrated amnion/chorion membrane allograft in patients who subsequently undergo reexploration after posterior lumbar instrumentation. Adv Orthop. 2015. Epub 2015 Jan 13.

Sui L, Xie Q, Jiang HT, Li XD. Effectiveness and safety of dermal matrix used for diabetic foot ulcer: a systematic review and meta-analysis of randomized controlled trials. BMC Endocr Disord. 2024;24(1):23.

Tausche AK, Skaria M, Böhlen L, et al. An autologous epidermal equivalent tissue-engineered from follicular outer root sheath keratinocytes is as effective as split-thickness skin autograft in recalcitrant vascular leg ulcers. Wound Repair Regen. 2003;11(4):248-252.

Tenenhaus M, Greenberg M, Potenza B. Dehydrated human amnion/chorion membrane for the treatment of severe skin and tissue loss in a preterm infant: a case report. J Wound Care. 2014;23(10):490-495.

Tettelbach W, Cazzell S, Reyzelman AM, et al. A confirmatory study on the efficacy of dehydrated human amnion/chorion membrane dHACM allograft in the management of diabetic foot ulcers: a prospective, multicentre, randomised, controlled study of 110 patients from 14 wound clinics. Int Wound J. 2019;16(1):19-29.

Tettelbach W, Cazzell S, Sigal F, et al. A multicentre prospective randomised controlled comparative parallel study of dehydrated human umbilical cord (EpiCord) allograft for the treatment of diabetic foot ulcers. Int Wound J. 2019;16(1):122-130.

Theodorakopoulos G, Armstrong DG. Collagen-ORC versus standard treatment in diabetic foot ulcers: a systematic review and meta-analysis of randomised trials. Int Wound J. 2025;22(11):e70782.

Trippoli S, Caccese E, Tulli G, et al. Biological meshes for abdominal hernia: Lack of evidence-based recommendations for clinical use. Int J Surg. 2018;52:278-284. 

Uccioli L, Giurato L, Ruotolo V, et al. Two-step autologous grafting using HYAFF scaffolds in treating difficult diabetic foot ulcers: results of a multicenter, randomized controlled clinical trial with long-term follow-up. Int J Low Extrem Wounds. 2011;10(2):80-85.

US Food and Drug Administration (FDA). Center for Devices and Radiological Health. Device approvals and clearances. [FDA Web site]. 11/06/2023. Available at: https://www.fda.gov/medical-devices/products-and-medical-procedures/device-approvals-and-clearances. Accessed April 3, 2026. ​

US Food and Drug Administration (FDA). FDA executive summary: prepared for the October 26 & 27, 2022 meeting of the general and plastic surgery devices panel of the medical devices advisory panel. [FDA Web site]. Available at: https://www.fda.gov/media/162539/download. Accessed April 3, 2026. 

US Food and Drug Administration (FDA). Humanitarian device exemption (HDE) postmarket activities. [FDA Web site]. 09/05/2019. Available at: https://www.fda.gov/medical-devices/humanitarian-device-exemption/humanitarian-device-exemption-hde-postmarket-activities. Accessed April 3, 2026. 

U.S. Food and Drug Administration (FDA). Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use. 07/21/2020. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal. Accessed April 3, 2026.

Vanstraelen P. Comparison of calcium sodium alginate (KALTOSTAT) and porcine xenograft (E-Z DERM) in the healing of split-thickness skin graft donor sites. Burns. 1992;18(2):145-148.

Veves A, Falanga V, Armstrong DG, et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001;24(2):290-295.

Vogel JD, Johnson EK, Morris AM, et al. Clinical practice guideline for the management of anorectal abscess, fistula-in-ano, and rectovaginal fistula. Dis Colon Rectum. 2016;59(12):1117-1133.

Wainwright D, Madden M, Luterman A, et al. Clinical evaluation of an acellular allograft dermal matrix in full-thickness burns. J Burn Care Rehabil. 1996;17(2):124-136.

Walters J, Cazzell S, Pham H, et al. Healing rates in a multicenter assessment of a sterile, room temperature, acellular dermal matrix versus conventional care wound management and an active comparator in the treatment of full-thickness diabetic foot ulcers. Eplasty. 2016;16:e10.

Warriner RA 3rd, Cardinal M, TIDE Investigators. Human fibroblast-derived dermal substitute: results from a treatment investigational device exemption (TIDE) study in diabetic foot ulcers. Adv Skin Wound Care. 2011;24(7):306-311.

Wax MK, Winslow CP, Andersen PE. Use of allogenic dermis for radial forearm free flap donor site coverage. J Otolaryngol. 2002;31(6):341-345.

Weigert R, Choughri H, Casoli V. Management of severe hand wounds with Integra® dermal regeneration template. J Hand Surg Eur Vol. 2011;36(3):185-193.

Whang KK, Kim MJ, Song WK, Cho S. Comparative treatment of giant congenital melanocytic nevi with curettage or Er:YAG laser ablation alone versus with cultured epithelial autografts. Dermatol Surg. 2005;31(12):1660-1667.

Williams N, Stiller K, Greenwood J, et al. Physical and quality of life outcomes of patients with isolated hand burns—a prospective audit. J Burn Care Res. 2012;33(2):188-198.

Williamson JS, Snelling CF, Clugston P, et al. Cultured epithelial autograft: five years of clinical experience with twenty-eight patients. J Trauma. 1995;39(2):309-319.

Winters CL, Brigido SA, Liden BA, et al. A multicenter study involving the use of a human acellular dermal regenerative tissue matrix for the treatment of diabetic lower extremity wounds. Adv Skin Wound Care. 2008;21(8):375-381.

Wood BC. Skin grafts and biologic skin substitutes. [Medscape Web site]. 10/16/2024. Available at: http://emedicine.medscape.com/article/1295109-overview. Accessed April 26, 2026.

Woodley DT, Peterson HD, Herzog SR, et al. Burn wounds resurfaced by cultured epidermal autografts show abnormal reconstitution of anchoring fibrils. JAMA. 1988;259(17):2566-2571.

Yim H, Cho YS, Seo CH, et al. The use of Alloderm on major burn patients: Alloderm prevents post-burn joint contracture. Burns. 2010;36(3):322-328.

Zelen CM. An evaluation of dehydrated human amniotic membrane allografts in patients with DFUs. J Wound Care. 2013;22(7):347-351.

Zelen CM, Gould L, Serena TE, et al. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers. Int Wound J. 2015;12(6):724-732.

Zelen CM, Orgill DP, Serena TE, et al. An aseptically processed, acellular, reticular, allogenic human dermis improves healing in diabetic foot ulcers: a prospective, randomised, controlled, multicentre follow-up trial. Int Wound J. 2018;15(5):731-739.

Zelen CM, Orgill DP, Serena TE, et al. A prospective, randomised, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers. Int Wound J. 2017;14(2):307-315.​

Zelen CM, Poka A, Andrews J. Prospective, randomized, blinded, comparative study of injectable micronized dehydrated amniotic/chorionic membrane allograft for plantar fasciitis--a feasibility study. Foot Ankle Int. 2013;34(10):1332-1339.

Zelen CM, Serena TE, Denoziere G, Fetterolf DE. A prospective randomized comparative parallel study of amniotic membrane wound graft in the management of diabetic foot ulcer. Int Wound J. 2013;10(5):502-507.

Zelen CM, Serena TE, Fetterolf DE. Dehydrated human amnion/chorion membrane allografts in patients with chronic diabetic foot ulcers: a long term follow-up study. Wound Medicine. 2014;4:1-4.

Zelen CM, Serena TE, Gould L, et al. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost. Int Wound J. 2016;13(2):272-282.

Zelen CM, Serena TE, Snyder RJ. A prospective, randomized comparative study of weekly versus biweekly application of dehydrated human amnion/chorion membrane allograft in the management of diabetic foot ulcers. Int Wound J. 2014;11(2):122-128.

Zelen CM, Snyder RJ, Serena TE, Li WW. The use of human amnion/chorion membrane in the clinical setting for lower extremity repair: a review. Clin Podiatr Med Surg. 2015;32(1):135-146.​

Zhong T, Janis JE, Ahmad J, Hofer SO. Outcomes after abdominal wall reconstruction using acellular dermal matrix: a systematic review. J Plast Reconstr Aesthet Surg. 2011;64(12):1562-1571.​​

Coding

CPT Procedure Code Number(s)
MEDICALLY NECESSARY
​
15011, 15012, 15013, 15014, 15015, 15016, 15017, 15018, 15150, 15151, 15152, 15155, 15156, 15157, 15271, 15272, 15273, 15274, 15275, 15276, 15277, 15278

EXPERIMENTAL/INVESTIGATIONAL

1044T, 1045T, 1046T, 1047T, 1048T, 1049T
ICD - 10 Procedure Code Number(s)
N/A
ICD - 10 Diagnosis Code Number(s)
Report the most appropriate diagnosis code in support of medically necessary criteria as listed in the policy.
HCPCS Level II Code Number(s)
MEDICALLY NECESSARY

A2001 Innovamatrix ac, per square centimeter (add-on, list separately in addition to primary procedure)

A2002 Mirragen advanced wound matrix, per square centimeter (add-on, list separately in addition to primary procedure)

A2004 Xcellistem, 1 mg

A2005 Microlyte matrix, per square centimeter (add-on, list separately in addition to primary procedure)

A2006 Novosorb synpath dermal matrix, per square centimeter (add-on, list separately in addition to primary procedure)

A2007 Restrata, per square centimeter (add-on, list separately in addition to primary procedure)

A2008 Theragenesis, per square centimeter (add-on, list separately in addition to primary procedure)

A2009 Symphony, per square centimeter (add-on, list separately in addition to primary procedure)

A2010 Apis, per square centimeter (add-on, list separately in addition to primary procedure)

A2011 Supra sdrm, per square centimeter (add-on, list separately in addition to primary procedure)

A2012 Suprathel, per square centimeter (add-on, list separately in addition to primary procedure)

A2013 Innovamatrix fs, per square centimeter (add-on, list separately in addition to primary procedure)

A2014 Omeza collagen matrix or omeza complete matrix, per 100 mg

A2015 Phoenix wound matrix, per square centimeter (add-on, list separately in addition to primary procedure)

A2016 Permeaderm b, per square centimeter (add-on, list separately in addition to primary procedure)

A2018 Permeaderm c, per square centimeter (add-on, list separately in addition to primary procedure)

A2019 Kerecis omega3 marigen shield, per square centimeter (add-on, list separately in addition to primary procedure)

A2020 Ac5 advanced wound system (ac5)

A2021 Neomatrix, per square centimeter (add-on, list separately in addition to primary procedure)

A2022 Innovaburn or innovamatrix xl, per square centimeter (add-on, list separately in addition to primary procedure)

A2023 Innovamatrix pd, 1 mg

A2024 Resolve matrix or xenopatch, per square centimeter (add-on, list separately in addition to primary procedure)

A2025 Miro3d, per cubic centimeter (add-on, list separately in addition to primary procedure)

A2026 Restrata minimatrix, 5 mg

A2027 Matriderm, per square centimeter (add-on, list separately in addition to primary procedure)

A2028 Micromatrix flex, per mg

A2029 Mirotract wound matrix sheet, per cubic centimeter (add-on, list separately in addition to primary procedure)

A2030 Miro3d fibers, per milligram

A2031 Mirodry wound matrix, per square centimeter (add-on, list separately in addition to primary procedure)

A2032 Myriad matrix, per square centimeter (add-on, list separately in addition to primary procedure)

A2033 Myriad morcells, 4 milligrams

A2034 Foundation drs solo, per square centimeter (add-on, list separately in addition to primary procedure)

A2035 Corplex p or theracor p or allacor p, per milligram

A2036 Cohealyx collagen dermal matrix, per square centimeter (add-on, list separately in addition to primary procedure)

A2037 G4derm plus/suprello, per milliliter

A2038 Marigen pacto, per square centimeter (add-on, list separately in addition to primary procedure)

A2039 Innovamatrix fd, per square centimeter (add-on, list separately in addition to primary procedure)

A2040 Microlyte Painguard, per square centimeter (add-on, list separately in addition to primary procedure)

A2041 Foundation DRS+ duo, per square centimeter (add-on, list separately in addition to primary procedure)

A2042 Foundation DRS+ solo, per square centimeter (add-on, list separately in addition to primary procedure)

A2043 Biobrane, per square centimeter (add-on, list separately in addition to primary procedure)

A2044 Biobrane glove, each

A2045 Novashield or Novogen wound matrix, per square centimeter (add-on, list separately in addition to primary procedure)

A2046 Dermisphere hdrt, per square centimeter (add-on, list separately in addition to primary procedure)

A2047 Lacertamatrix, per square centimeter (add-on, list separately in addition to primary procedure)

A2048 Puraply mz, per milligram

A2049 Theracor, per square centimeter (add-on, list separately in addition to primary procedure)

A2050 Fibrillar collagen wound dressing, per milligram

C9358 Dermal substitute, native, nondenatured collagen, fetal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm

C9360 Dermal substitute, native, nondenatured collagen, neonatal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm

C9363 Skin substitute (Integra Meshed Bilayer Wound Matrix), per square cm

C9364 Porcine implant, Permacol, per sq cm

G0681 Application of a premarket approval (pma), 510(k), 361 human cells, tissues or cellular and tissue-based products (hct/p) non-sheet form skin substitute for a wound surface area up to 100 sq cm; first 25 sq cm or less of wound surface area

G0682 Application of a premarket approval (pma), 510(k), 361 human cells, tissues or cellular and tissue-based products (hct/p) non-sheet form skin substitute for a wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof (list separately in addition to code for primary procedure)

G0683 Application of a premarket approval (pma), 510(k), 361 human cells, tissues or cellular and tissue-based products (hct/p) non-sheet form skin substitute graft for a wound surface greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children

G0684 Application of a premarket approval (pma), 510(k), 361 human cells, tissues or cellular and tissue-based products (hct/p) non-sheet form skin substitute graft for a wound surface greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area or part thereof, or each additional 1% of body area of infants and children, or part thereof (list separately in addition to code for primary procedure)

Q4101 Apligraf, per square centimeter (add-on, list separately in addition to primary procedure)

Q4102 Oasis wound matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4103 Oasis burn matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4104 Integra bilayer matrix wound dressing (bmwd), per square centimeter (add-on, list separately in addition to primary procedure)

Q4105 Integra dermal regeneration template (drt) or integra omnigraft dermal regeneration matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4107 Graftjacket, per square centimeter (add-on, list separately in addition to primary procedure)

Q4108 Integra matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4110 Primatrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4111 Gammagraft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4113 GRAFTJACKET XPRESS, injectable, 1cc

Q4115 Alloskin, per square centimeter (add-on, list separately in addition to primary procedure)

Q4117 Hyalomatrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4118 MatriStem micromatrix, 1 mg

G4121 Theraskin, per square centimeter (add-on, list separately in addition to primary procedure)

G4122 Dermacell, dermacell awm or dermacell awm porous, per square centimeter (add-on, list separately in addition to primary procedure)

Q4123 Alloskin rt, per square centimeter (add-on, list separately in addition to primary procedure)

Q4124 Oasis ultra tri-layer wound matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4126 Memoderm, dermaspan, tranzgraft or integuply, per square centimeter (add-on, list separately in addition to primary procedure)

Q4127 Talymed, per square centimeter (add-on, list separately in addition to primary procedure)

Q4128 Flex hd, or allopatch hd, per square centimeter (add-on, list separately in addition to primary procedure)

Q4130 Strattice, per sq cm (add-on, list separately in addition to primary procedure)

Q4132 Grafix core and grafixpl core, per square centimeter (add-on, list separately in addition to primary procedure)

Q4133 Grafix prime, grafixpl prime, stravix and stravixpl, per square centimeter (add-on, list separately in addition to primary procedure)

Q4134 Hmatrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4135 Mediskin, per square centimeter (add-on, list separately in addition to primary procedure)

Q4136 Ez-derm, per square centimeter (add-on, list separately in addition to primary procedure)

Q4137 Amnioexcel, amnioexcel plus or biodexcel, per square centimeter (add-on, list separately in addition to primary procedure)

Q4138 BioDFence dryflex, per square centimeter (add-on, list separately in addition to primary procedure)

Q4139 AmnioMatrix or BioDMatrix, injectable, 1 cc

Q4140 Biodfence, per square centimeter (add-on, list separately in addition to primary procedure)

Q4141 Alloskin ac, per square centimeter (add-on, list separately in addition to primary procedure)

Q4142 XCM biologic tissue matrix, per sq cm (add-on, list separately in addition to primary procedure)

Q4143 Repriza, per sq cm (add-on, list separately in addition to primary procedure)

Q4145 EpiFix, injectable, 1 mg

Q4146 Tensix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4147 Architect, architect px, or architect fx, extracellular matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4148 Neox cord 1k, neox cord rt, or clarix cord 1k, per square centimeter (add-on, list separately in addition to primary procedure)

Q4149 Excellagen, 0.1 cc

Q4150 Allowrap ds or dry, per square centimeter (add-on, list separately in addition to primary procedure)

Q4151 Amnioband or guardian, per square centimeter (add-on, list separately in addition to primary procedure)

Q4152 Dermapure, per square centimeter (add-on, list separately in addition to primary procedure)

Q4153 Dermavest and plurivest, per square centimeter (add-on, list separately in addition to primary procedure)

Q4154 Biovance, per square centimeter (add-on, list separately in addition to primary procedure)

Q4155 Neox Flo or Clarix Flo, 1 mg

Q4156 Neox 100 or clarix 100, per square centimeter (add-on, list separately in addition to primary procedure)

Q4157 Revitalon, per square centimeter (add-on, list separately in addition to primary procedure)

Q4158 Kerecis omega3, per square centimeter (add-on, list separately in addition to primary procedure)

Q4159 Affinity, per square centimeter (add-on, list separately in addition to primary procedure)

Q4160 Nushield, per square centimeter (add-on, list separately in addition to primary procedure)

Q4161 Bio-connekt wound matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4162 WoundEx Flow, BioSkin Flow, 0.5 cc

Q4163 Woundex, bioskin, per square centimeter (add-on, list separately in addition to primary procedure)

Q4164 Helicoll, per square centimeter (add-on, list separately in addition to primary procedure)

Q4165 Keramatrix or kerasorb, per square centimeter (add-on, list separately in addition to primary procedure)

Q4166 Cytal, per square centimeter (add-on, list separately in addition to primary procedure)

Q4167 Truskin, per square centimeter (add-on, list separately in addition to primary procedure)

Q4168 AmnioBand, 1 mg

Q4169 Artacent wound, per square centimeter (add-on, list separately in addition to primary procedure)

Q4170 Cygnus, per square centimeter (add-on, list separately in addition to primary procedure)

Q4171 Interfyl, 1 mg

Q4173 Palingen or palingen xplus, per square centimeter (add-on, list separately in addition to primary procedure)

Q4174 PalinGen or ProMatrX, 0.36 mg per 0.25 cc

Q4175 Miroderm, per square centimeter (add-on, list separately in addition to primary procedure)

Q4176 Neopatch or therion, per square centimeter (add-on, list separately in addition to primary procedure)

Q4177 Floweramnioflo, 0.1 cc

Q4178 Floweramniopatch, per square centimeter (add-on, list separately in addition to primary procedure)

Q4179 Flowerderm, per square centimeter (add-on, list separately in addition to primary procedure)

Q4180 Revita, per square centimeter (add-on, list separately in addition to primary procedure)

Q4181 Amnio wound, per square centimeter (add-on, list separately in addition to primary procedure)

Q4182 Transcyte, per square centimeter (add-on, list separately in addition to primary procedure)

Q4183 Surgigraft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4184 Cellesta or cellesta duo, per square centimeter (add-on, list separately in addition to primary procedure)

Q4185 Cellesta flowable amnion (25 mg per cc); per 0.5 cc

Q4186 Epifix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4187 Epicord, per square centimeter (add-on, list separately in addition to primary procedure)

Q4188 Amnioarmor, per square centimeter (add-on, list separately in addition to primary procedure)

Q4189 Artacent ac, 1 mg

Q4190 Artacent ac, per square centimeter (add-on, list separately in addition to primary procedure)

Q4191 Restorigin, per square centimeter (add-on, list separately in addition to primary procedure)

Q4192 Restorigin, 1 cc

Q4193 Coll-e-derm, per square centimeter (add-on, list separately in addition to primary procedure)

Q4194 Novachor, per square centimeter (add-on, list separately in addition to primary procedure)

Q4195 Puraply, per square centimeter (add-on, list separately in addition to primary procedure)

Q4196 Puraply am, per square centimeter (add-on, list separately in addition to primary procedure)

Q4197 Puraply xt, per square centimeter (add-on, list separately in addition to primary procedure)

Q4198 Genesis amniotic membrane, per square centimeter (add-on, list separately in addition to primary procedure)

Q4199 Cygnus matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4200 Skin te, per square centimeter (add-on, list separately in addition to primary procedure)

Q4201 Matrion, per square centimeter (add-on, list separately in addition to primary procedure)

Q4202 Keroxx (2.5g/cc), 1cc

Q4203 Derma-gide, per square centimeter (add-on, list separately in addition to primary procedure)

Q4204 Xwrap, per square centimeter (add-on, list separately in addition to primary procedure)

Q4205 Membrane graft or membrane wrap, per square centimeter (add-on, list separately in addition to primary procedure)

Q4206 Fluid flow or fluid GF, 1 cc

Q4207 Carbon life, per square centimeter (add-on, list separately in addition to primary procedure)

Q4208 Novafix, per square cenitmeter (add-on, list separately in addition to primary procedure)

Q4209 Surgraft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4211 Amnion bio or axobiomembrane, per square centimeter (add-on, list separately in addition to primary procedure)

Q4212 Allogen, per cc

Q4213 Ascent, 0.5 mg

Q4214 Cellesta cord, per square centimeter (add-on, list separately in addition to primary procedure)

Q4215 Axolotl ambient or axolotl cryo, 0.1 mg

Q4216 Artacent cord, per square centimeter (add-on, list separately in addition to primary procedure)

Q4217 Woundfix, biowound, woundfix plus, biowound plus, woundfix xplus or biowound xplus, per square centimeter (add-on, list separately in addition to primary procedure)

Q4218 Surgicord, per square centimeter (add-on, list separately in addition to primary procedure)

Q4219 Surgigraft-dual, per square centimeter (add-on, list separately in addition to primary procedure)

Q4220 Bellacell hd or surederm, per square centimeter (add-on, list separately in addition to primary procedure)

Q4221 Amniowrap2, per square centimeter (add-on, list separately in addition to primary procedure)

Q4222 Progenamatrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4223 Dermabind sl optic, per square centimeter (add-on, list separately in addition to primary procedure)

Q4224 Human health factor 10 amniotic patch (hhf10-p), per square centimeter (add-on, list separately in addition to primary procedure)

Q4225 Amniobind or dermabind tl, per square centimeter (add-on, list separately in addition to primary procedure)

Q4226 MyOwn skin, includes harvesting and preparation procedures, per square centimeter

Q4227 Amniocore, per square centimeter (add-on, list separately in addition to primary procedure)

Q4229 Cogenex amniotic membrane, per square centimeter (add-on, list separately in addition to primary procedure)

Q4230 Cogenex flowable amnion, per 0.5 cc

Q4232 Corplex, per square centimeter (add-on, list separately in addition to primary procedure)

Q4233 Surfactor or Nudyn, per 0.5 cc

Q4234 Xcellerate, per square centimeter (add-on, list separately in addition to primary procedure)

Q4235 Amniorepair or altiply, per square centimeter (add-on, list separately in addition to primary procedure)

Q4236 Carepatch, per square centimeter (add-on, list separately in addition to primary procedure)

Q4237 Cryo-cord, per square centimeter (add-on, list separately in addition to primary procedure)

Q4238 Derm-maxx, per square centimeter (add-on, list separately in addition to primary procedure)

Q4239 Amnio-maxx or amnio-maxx lite, per square centimeter (add-on, list separately in addition to primary procedure)

Q4240 Corecyte, for topical use only, per 0.5 cc

Q4241 Polycyte, for topical use only, per 0.5 cc

Q4242 Amniocyte plus, per 0.5 cc

Q4243 Amchomatrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4245 Amniotext, per cc

Q4246 Coretext or protext, per cc

Q4247 Amniotext patch, per square centimeter (add-on, list separately in addition to primary procedure)

Q4248 Dermacyte amniotic membrane allograft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4249 Amniply, for topical use only, per square centimeter (add-on, list separately in addition to primary procedure)

Q4250 Amnioamp-mp, per square centimeter (add-on, list separately in addition to primary procedure)

Q4251 Vim, per square centimeter (add-on, list separately in addition to primary procedure)

Q4252 Vendaje, per square centimeter (add-on, list separately in addition to primary procedure)

Q4253 Zenith amniotic membrane, per square centimeter (add-on, list separately in addition to primary procedure)

Q4254 Novafix dl, per square centimeter (add-on, list separately in addition to primary procedure)

Q4255 Reguard, for topical use only, per square centimeter (add-on, list separately in addition to primary procedure)

Q4256 Mlg-complete, per square centimeter (add-on, list separately in addition to primary procedure)

Q4257 Relese, per square centimeter (add-on, list separately in addition to primary procedure)

Q4258 Enverse, per square centimeter (add-on, list separately in addition to primary procedure)

Q4259 Celera dual layer or celera dual membrane, per square centimeter (add-on, list separately in addition to primary procedure)

Q4260 Signature apatch, per square centimeter (add-on, list separately in addition to primary procedure)

Q4261 Tag, per square centimeter (add-on, list separately in addition to primary procedure)

Q4262 Dual layer impax membrane, per square centimeter (add-on, list separately in addition to primary procedure)

Q4263 Surgraft tl, per square centimeter (add-on, list separately in addition to primary procedure)

Q4264 Cocoon membrane, per square centimeter (add-on, list separately in addition to primary procedure)

Q4265 Neostim tl, per square centimeter (add-on, list separately in addition to primary procedure)

Q4266 Neostim membrane, per square centimeter (add-on, list separately in addition to primary procedure)

Q4267 Neostim dl, per square centimeter (add-on, list separately in addition to primary procedure)

Q4268 Surgraft ft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4269 Surgraft xt, per square centimeter (add-on, list separately in addition to primary procedure)

Q4270 Complete sl, per square centimeter (add-on, list separately in addition to primary procedure)

Q4271 Complete ft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4272 Esano a, per square centimeter (add-on, list separately in addition to primary procedure)

Q4273 Esano aaa, per square centimeter (add-on, list separately in addition to primary procedure)

Q4274 Esano ac, per square centimeter (add-on, list separately in addition to primary procedure)

Q4275 Esano aca, per square centimeter (add-on, list separately in addition to primary procedure)

Q4276 Orion, per square centimeter (add-on, list separately in addition to primary procedure)

Q4278 Epieffect, per square centimeter (add-on, list separately in addition to primary procedure)

Q4279 Vendaje ac, per square centimeter (add-on, list separately in addition to primary procedure)

Q4280 Xcell amnio matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4281 Barrera sl or barrera dl, per square centimeter (add-on, list separately in addition to primary procedure)

Q4282 Cygnus dual, per square centimeter (add-on, list separately in addition to primary procedure)

Q4283 Biovance tri-layer or biovance 3l, per square centimeter (add-on, list separately in addition to primary procedure)

Q4284 Dermabind sl, per square centimeter (add-on, list separately in addition to primary procedure)

Q4285 Nudyn dl or nudyn dl mesh, per square centimeter (add-on, list separately in addition to primary procedure)

Q4286 Nudyn sl or nudyn slw, per square centimeter (add-on, list separately in addition to primary procedure)

Q4287 Dermabind dl, per square centimeter (add-on, list separately in addition to primary procedure)

Q4288 Dermabind ch, per square centimeter (add-on, list separately in addition to primary procedure)

Q4289 Revoshield + amniotic barrier, per square centimeter (add-on, list separately in addition to primary procedure)

Q4290 Membrane wrap-hydro, per square centimeter (add-on, list separately in addition to primary procedure)

Q4291 Lamellas xt, per square centimeter (add-on, list separately in addition to primary procedure)

Q4292 Lamellas, per square centimeter (add-on, list separately in addition to primary procedure)

Q4293 Acesso dl, per square centimeter (add-on, list separately in addition to primary procedure)

Q4294 Amnio quad-core, per square centimeter (add-on, list separately in addition to primary procedure)

Q4295 Amnio tri-core amniotic, per square centimeter (add-on, list separately in addition to primary procedure)

Q4296 Rebound matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4297 Emerge matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4298 Amnicore Pro, per square centimeter (add-on, list separately in addition to primary procedure)

Q4299 Amnicore Pro+, per square centimeter (add-on, list separately in addition to primary procedure)

Q4300 Acesso tl, per square centimeter (add-on, list separately in addition to primary procedure)

Q4301 Activate matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4302 Complete aca, per square centimeter (add-on, list separately in addition to primary procedure)

Q4303 Complete aa, per square centimeter (add-on, list separately in addition to primary procedure)

Q4304 Grafix plus, per square centimeter (add-on, list separately in addition to primary procedure)

Q4305 American amnion ac tri-layer, per square centimeter (add-on, list separately in addition to primary procedure)

Q4306 American amnion ac, per square centimeter (add-on, list separately in addition to primary procedure)

Q4307 American amnion, per square centimeter (add-on, list separately in addition to primary procedure)

Q4308 Sanopellis, per square centimeter (add-on, list separately in addition to primary procedure)

Q4309 Via matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4310 Procenta, per 100 mg

Q4311 Acesso, per square centimeter (add-on, list separately in addition to primary procedure)

Q4312 Acesso ac, per square centimeter (add-on, list separately in addition to primary procedure)

Q4313 Dermabind fm, per square centimeter (add-on, list separately in addition to primary procedure)

Q4314 Reeva ft, per square cenitmeter (add-on, list separately in addition to primary procedure)

Q4315 Regenelink amniotic membrane allograft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4316 Amchoplast, per square centimeter (add-on, list separately in addition to primary procedure)

Q4317 Vitograft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4318 E-graft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4319 Sanograft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4320 Pellograft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4321 Renograft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4322 Caregraft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4323 Alloply, per square centimeter (add-on, list separately in addition to primary procedure)

Q4324 Amniotx, per square centimeter (add-on, list separately in addition to primary procedure)

Q4325 Acapatch, per square centimeter (add-on, list separately in addition to primary procedure)

Q4326 Woundplus, per square centimeter (add-on, list separately in addition to primary procedure)

Q4327 Duoamnion, per square centimeter (add-on, list separately in addition to primary procedure)

Q4328 Most, per square centimeter (add-on, list separately in addition to primary procedure)

Q4329 Singlay, per square centimeter (add-on, list separately in addition to primary procedure)

Q4330 Total, per square centimeter (add-on, list separately in addition to primary procedure)

Q4331 Axolotl graft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4332 Axolotl dualgraft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4333 Ardeograft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4334 Amnioplast 1, per square centimeter (add-on, list separately in addition to primary procedure)

Q4335 Amnioplast 2, per square centimeter (add-on, list separately in addition to primary procedure)

Q4336 Artacent c, per square centimeter (add-on, list separately in addition to primary procedure)

Q4337 Artacent trident, per square centimeter (add-on, list separately in addition to primary procedure)

Q4338 Artacent velos, per square centimeter (add-on, list separately in addition to primary procedure)

Q4339 Artacent vericlen, per square centimeter (add-on, list separately in addition to primary procedure)

Q4340 Simpligraft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4341 Simplimax, per square centimeter (add-on, list separately in addition to primary procedure)

Q4342 Theramend, per square centimeter (add-on, list separately in addition to primary procedure)

Q4343 Dermacyte ac matrix amniotic membrane allograft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4344 Tri-membrane wrap, per square centimeter (add-on, list separately in addition to primary procedure)

Q4345 Matrix hd allograft dermis, per square centimeter (add-on, list separately in addition to primary procedure)

Q4346 Shelter dm matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4347 Rampart dl matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4348 Sentry sl matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4349 Mantle dl matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4350 Palisade dm matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4351 Enclose tl matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4352 Overlay sl matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4353 Xceed tl matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4354 Palingen dual-layer membrane, per square centimeter (add-on, list separately in addition to primary procedure)

Q4355 Abiomend xplus membrane and abiomend xplus hydromembrane, per square centimeter (add-on, list separately in addition to primary procedure)

Q4356 Abiomend membrane and abiomend hydromembrane, per square centimeter (add-on, list separately in addition to primary procedure)

Q4357 Xwrap plus, per square centimeter (add-on, list separately in addition to primary procedure)

Q4358 Xwrap dual, per square centimeter (add-on, list separately in addition to primary procedure)

Q4359 Choriply, per square centimeter (add-on, list separately in addition to primary procedure)

Q4360 Amchoplast fd, per square centimeter (add-on, list separately in addition to primary procedure)

Q4361 Epixpress, per square centimeter (add-on, list separately in addition to primary procedure)

Q4362 Cygnus disk, per square centimeter (add-on, list separately in addition to primary procedure)

Q4363 Amnio burgeon membrane and hydromembrane, per square centimeter (add-on, list separately in addition to primary procedure)

Q4364 Amnio burgeon xplus membrane and xplus hydromembrane, per square centimeter (add-on, list separately in addition to primary procedure)

Q4365 Amnio burgeon dual-layer membrane, per square centimeter (add-on, list separately in addition to primary procedure)

Q4366 Dual layer amnio burgeon x-membrane, per square centimeter (add-on, list separately in addition to primary procedure)

Q4367 Amniocore sl, per square centimeter (add-on, list separately in addition to primary procedure)

Q4368 Amchothick, per square centimeter (add-on, list separately in addition to primary procedure)

Q4369 Amnioplast 3, per square centimeter (add-on, list separately in addition to primary procedure)

Q4370 Aeroguard, per square centimeter (add-on, list separately in addition to primary procedure)

Q4371 Neoguard, per square centimeter (add-on, list separately in addition to primary procedure)

Q4372 Amchoplast excel, per square centimeter (add-on, list separately in addition to primary procedure)

Q4373 Membrane wrap lite, per square centimeter (add-on, list separately in addition to primary procedure)

Q4375 Duograft ac, per square centimeter (add-on, list separately in addition to primary procedure)

Q4376 Duograft aa, per square centimeter (add-on, list separately in addition to primary procedure)

Q4377 Trigraft ft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4378 Renew ft matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4379 Amniodefend ft matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4380 Advograft one, per square centimeter (add-on, list separately in addition to primary procedure)

Q4382 Advograft dual, per square centimeter (add-on, list separately in addition to primary procedure)

Q4383 Axolotl graft ultra, per square centimeter (add-on, list separately in addition to primary procedure)

Q4384 Axolotl dualgraft ultra, per square centimeter (add-on, list separately in addition to primary procedure)

Q4385 Apollo ft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4386 Acesso trifaca, per square centimeter (add-on, list separately in addition to primary procedure)

Q4387 Neothelium ft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4388 Neothelium 4l, per square centimeter (add-on, list separately in addition to primary procedure)

Q4389 Neothelium 4l+, per square centimeter (add-on, list separately in addition to primary procedure)

Q4390 Ascendion, per square centimeter (add-on, list separately in addition to primary procedure)

Q4391 Amnioplast double, per square centimeter (add-on, list separately in addition to primary procedure)

Q4392 Grafix duo, per square centimeter (add-on, list separately in addition to primary procedure)

Q4393 Surgraft ac, per square centimeter (add-on, list separately in addition to primary procedure)

Q4394 Surgraft aca, per square centimeter (add-on, list separately in addition to primary procedure)

Q4395 Acelagraft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4396 Natalin, per square centimeter (add-on, list separately in addition to primary procedure)

Q4397 Summit aaa, per square centimeter (add-on, list separately in addition to primary procedure)

Q4398 Summit ac, per square centimeter (add-on, list separately in addition to primary procedure)

Q4399 Summit fx, per square centimeter (add-on, list separately in addition to primary procedure)

Q4400 Polygon3 membrane, per square centimeter (add-on, list separately in addition to primary procedure)

Q4401 Absolv3 membrane, per square centimeter (add-on, list separately in addition to primary procedure)

Q4402 Xwrap 2.0, per square centimeter (add-on, list separately in addition to primary procedure)

Q4403 Xwrap dual plus, per square centimeter (add-on, list separately in addition to primary procedure)

Q4404 Xwrap hydro plus, per square centimeter (add-on, list separately in addition to primary procedure)

Q4405 Xwrap fenestra plus, per square centimeter (add-on, list separately in addition to primary procedure)

Q4406 Xwrap fenestra, per square centimeter (add-on, list separately in addition to primary procedure)

Q4407 Xwrap tribus, per square centimeter (add-on, list separately in addition to primary procedure)

Q4408 Xwrap hydro, per square centimeter (add-on, list separately in addition to primary procedure)

Q4409 Amniomatrixf3x, per square centimeter (add-on, list separately in addition to primary procedure)

Q4410 Amchomatrixdl, per square centimeter (add-on, list separately in addition to primary procedure)

Q4411 Amniomatrixf4x, per square centimeter (add-on, list separately in addition to primary procedure)

Q4412 Choriofix, per square centimeter (add-on, list separately in addition to primary procedure)

Q4413 Cygnus solo, per square centimeter (add-on, list separately in addition to primary procedure)

Q4414 Simplichor, per square centimeter (add-on, list separately in addition to primary procedure)

Q4415 Alexiguard sl-t, per square centimeter (add-on, list separately in addition to primary procedure)

Q4416 Alexiguard tl-t, per square centimeter (add-on, list separately in addition to primary procedure)

Q4417 Alexiguard dl-t, per square centimeter (add-on, list separately in addition to primary procedure)

Q4418 Biolab membrane wrap flow, per square centimeter (add-on, list separately in addition to primary procedure)

Q4419 Biolab membrane wrap lite flow, per square centimeter (add-on, list separately in addition to primary procedure)

Q4420 Nuform, per square centimeter (add-on, list separately in addition to primary procedure)

Q4421 Biolab membrane wrap solo, per square centimeter (add-on, list separately in addition to primary procedure)

Q4422 A/c wrap, per square centimeter (add-on, list separately in addition to primary procedure)

Q4423 Biolab tri-membrane wrap flow, per square centimeter (add-on, list separately in addition to primary procedure)

Q4424 Revive ft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4425 Revive tl, per square centimeter (add-on, list separately in addition to primary procedure)

Q4426 Dermabind tl + or dermabind tl x,  per square centimeter (add-on, list separately in addition to primary procedure)

Q4427 Dermabind dl n or dermabind dl + or dermabind dl x, per square centimeter (add-on, list separately in addition to primary procedure)

Q4428 Dermabind sl n or dermabind sl + or dermabind sl x, per square centimeter (add-on, list separately in addition to primary procedure)

Q4429 Dermabind ch n or dermabind ch x, per square centimeter (add-on, list separately in addition to primary procedure)

Q4435 Renati membrane, per square centimeter (add-on, list separately in addition to primary procedure)

Q4436 Renati ac membrane, per square centimeter (add-on, list separately in addition to primary procedure)

Q4437 Revival ac, per square centimeter (add-on, list separately in addition to primary procedure)

Q4438 Pretect, per square centimeter (add-on, list separately in addition to primary procedure)

Q4439 Instagraft, per square centimeter (add-on, list separately in addition to primary procedure)

Q4440 Curamatrix, per square centimeter (add-on, list separately in addition to primary procedure)


THE FOLLOWING CODES ARE USED TO REPRESENT RECELL AUTOLOGOUS CELL HARVESTING DEVICE

C1832 Autograft suspension, including cell processing and application, and all system components

C8002 Preparation of skin cell suspension autograft, automated, including all enzymatic processing and device components (do not report with manual suspension preparation)


THE FOLLOWING CODE IS USED TO REPRESENT DENOVOSKIN, EXPRESSGRAFT, REGENEPRO, STRATAGRAFT

A4100 Skin substitute, fda cleared as a device, not otherwise specified (list in addition to primary procedure)


THE FOLLOWING CODE IS USED TO REPRESENT ACELL UBM HYDRATED/LYOPHILIZED WOUND DRESSING, AONGEN COLLAGEN MATRIX, COLLAGEN WOUND DRESSING (OASIS RESEARCH), COLLAGUARD, COLLAWOUND, COLLEXA, COLLIEVA, DERMADAPT WOUND DRESSING, DRESSSKIN, ENDOFORM DERMAL TEMPLATE, MIRODERM BIOLOGIC WOUND MATRIX, THERAFORM STANDARD/SHEET

Q4432 510(k) skin substitute product, not otherwise specified


THE FOLLOWING CODE IS USED TO REPRESENT mVASC

Q4433 361 hct/p skin substitute product, not otherwise specified (list in addition to primary procedure)


EXPERIMENTAL/INVESTIGATIONAL

A2017 Permeaderm glove, each
Revenue Code Number(s)
N/A


Coding and Billing Requirements

Policy History

Revisions From MA11.015ah:
10/01/2026This version of the policy will become effective​ 10/01/2026.

  • The criteria for chronic lower extremity wounds, required documentation, and billing requirements have been revised to be a direct adoption of Centers for Medicare and Medicaid Services (CMS) criteria.
  • A note with​ the CMS definition of a failed response was added for additional clarity
  • Biobrane glove was added as a medically necessary treatment for second- and third-degree burns.
  • Experimental/investigational statements were revised and moved to be listed under each applicable indication. These include the statement that the use of bioengineered skin substitutes other than those specified in the policy (such as, but not limited to, acute wounds, post-Moh's, post-surgical use) are considered​ experimental/investigational.
  • A discussion of humanitarian device exemptions (HDEs)/humanitarian use devices (HUDs) was added into the policy.
  • The following HCPCS codes were added to this policy as eligible for coverage: A2005, A2006, A2020, A2029, A2046, A2047, A2048, A2049, A2050, C1832, C9358, C9360, C9364, Q4130, Q4138, Q4142, Q4143​, Q4150, Q4207, Q4212, Q4213, Q4223, Q4226, Q4233, Q4240, Q4241, Q4242, Q4243, Q4285, Q4286, Q4313, Q4315, Q4316, Q4323, Q4324, Q4334, Q4335, Q4343, Q4346, Q4347, Q4348, Q4349, Q4350, Q4351, Q4352, Q4353, Q4360, Q4369, Q4391​
  • The following CPT codes were added to this policy as experimental/investigational: 1044T, 1045T, 1046T, 1047T, 1048T, 1049T​
  • The effective date for the following HCPCS codes was revised to 01/01/2026: G0681, G0682, G0683, G0684
  • The following HCPCS codes have been revised in this policy:

    • A2040, A2041, A2042, A2043, A2045, Q4298, Q4299


Revisions From MA​11.015ag:
​04/01/2026
​This policy has been identified for the ​HCPCS code update, effective 04/01/2026.

The following HCPCS codes have been added to this policy: A2040, A2041, A2042, A2043, A2044, A2045, G0681, G0682, G0683, G0684, Q4418, Q4419, Q4421, Q4422, Q4423, Q4424, Q4425, Q4426, Q4427, Q4428, Q4429, Q4435, Q4436, Q4437, Q4438, Q4439, Q4440.​

The narratives of the following HCPCS codes have been revised in this policy: A2014, A2037.

Revisions From MA​11.015af:
​01/01/2026
​This policy has been identified for the ​HCPCS code update, effective 01/01/2026.

The following HCPCS codes have been added to this policy: Q4398, Q4399, Q4400, Q4401, Q4402, Q4403, Q4404, Q4405, Q4406, Q4407, Q4408, Q4409, Q4410, Q4411, Q4412, Q4413, Q4414, Q4415, Q4416, Q4417, Q4420, Q4431, Q4432, Q4433.

The following HCPCS codes have been terminated (effective 01/01/2026) and removed from this policy: C5271, C5272, C5273, C5274, C5275, C5276, C5277, C5278, Q4100, Q4106.

As a result of HCPCS code Q4100 being terminated, Epicel is now represented by HCPCS code A4100.

As a result of HCPCS code Q4100 being terminated, Biobrane and Orcel are now represented by new HCPCS code Q4431.

The narratives of the following HCPCS codes have been revised in this policy: A2001, A2002, A2007, A2008, A2009, A2010, A2011, A2012, A2013, A2015, A2016, A2018, A2019, A2021, A2022, A2024, A2025, A2027, A2031, A2032, A2034, A2036, A2038, A2039, A4100, Q4101, Q4102, Q4103, Q4104, Q4105, Q4107, Q4108, Q4110, Q4111, Q4115, Q4117, Q4121, Q4122, Q4123, Q4124, Q4126, Q4127, Q4128, Q4132, Q4133, Q4134, Q4135, Q4136, Q4137, Q4140, Q4141, Q4146, Q4147, Q4148, Q4151, Q4152, Q4153, Q4154, Q4156, Q4157, Q4158, Q4159, Q4160, Q4161, Q4163, Q4164, Q4165, Q4166, Q4167, Q4169, Q4170, Q4173, Q4175, Q4176, Q4178, Q4179, Q4180, Q4181, Q4182, Q4183, Q4184, Q4186, Q4187, Q4188, Q4190, Q4191, Q4193, Q4194, Q4195, Q4196, Q4197, Q4198, Q4199, Q4200, Q4201, Q4203, Q4204, Q4205, Q4208, Q4209, Q4211, Q4214, Q4216, Q4217, Q4218, Q4219, Q4220, Q4221, Q4222, Q4224, Q4225, Q4227, Q4229, ​Q4232, Q4234, Q4235, Q4236, Q4237, Q4238, Q4239, Q4247, Q4248, Q4249, Q4250, Q4251, Q4252, Q4253, Q4254, Q4255, Q4256, Q4257, Q4258, Q4259, Q4260, Q4261, Q4262, Q4263, Q4264, Q4265, Q4266, Q4267, Q4268, Q4269, Q4270, Q4271, Q4272, Q4273, Q4274, Q4275, Q4276, Q4278, Q4279, Q4280, Q4281, Q4282, Q4283, Q4284, Q4287, Q4288, Q4289, Q4290, Q4291, Q4292, Q4293, Q4294, Q4295, Q4296, Q4297, Q4298, Q4299, Q4300, Q4301, Q4302, Q4303, Q4304, Q4305, Q4306, Q4307, Q4308, Q4309, Q4311, Q4312, Q4314, Q4317, Q4318, Q4319, Q4320, Q4321, Q4322, Q4325, Q4326, Q4327, Q4328, Q4329, Q4330, Q4331, Q4332, Q4333, Q4336, Q4337, Q4338, Q4339, Q4340, Q4341, Q4342, Q4344, Q4345, Q4354, Q4355, Q4356, Q4357, Q4358, Q4359, Q4361, Q4362, Q4363, Q4364, Q4365, Q4366, Q4367, Q4368, Q4370, Q4371, Q4372, Q4373, Q4375, Q4376, Q4377, Q4378, Q4379, Q4380, Q4382, Q4383, Q4384, Q4385, Q4386, Q4387, Q4388, Q4389, Q4390, Q4392, Q4393, Q4394, Q4395, Q4396, Q4397.

Revisions From MA11.015ae:
​12/19/2025This policy has been reissued in accordance with the Company's annual review process.​
​10/01/2025
​This policy has been identified for the ​HCPCS code update, effective 10/01/2025.

The following HCPCS codes have been added to this policy as Medically Necessary: A2036, A2037, A2038, A2039, Q4383, Q4384, Q4385, Q4386, Q4387, Q4388, Q4389, Q4390, Q4392, Q4393, Q4394, Q4395, Q4396, Q4397.

Revisions From MA11.015ad:
07/01/2025This policy has been identified for the ​HCPCS code update, effective 07/01/2025.

The following HCPCS codes have been added to this policy as Medically Necessary:
Q4368, Q4370, Q4371, Q4372, Q4373, Q4375, Q4376, Q4377, Q4378, Q4379, Q4380, Q4382.​

Revisions From MA11.015ac:
04/01/2025This policy has been identified for the ​HCPCS code update, effective 04/01/2025.

The following HCPCS codes have been added to this policy as Medically Necessary:
A2030, A2031, A2032, A2033, A2034, A2035, Q4354, Q4355, Q4356, Q4357, Q4358, Q4359, Q4361, Q4362, Q4363, Q4364, Q4365, Q4366, Q4367.

Myriad Matrix was removed from the list of skin substitutes reported using HCPCS Code Q4100​.

The following HCPCS code has been termed and removed from this policy: Q4231.​

Revisions From MA11.015ab:
01/01/2025This policy has been identified for the CPT and HCPCS code update, effective 01/01/2025.

The following CPT codes have been added to this policy as Medically Necessary:
15011, 15012, 15013, 15014, 15015, 15016,15017, 15018

The following HCPCS code has been added to this policy as Medically Necessary:
C8002​

Revisions From MA11.015aa:
10/01/2024This policy has been identified for the HCPCS code update, effective 10/01/2024.

The following HCPCS codes have been added to this policy as Medically Necessary: A2027, A2028, Q4336, Q4337, Q4338, Q4339, Q4340, Q4341, Q4342, Q4344, Q4345.

The following HCPCS code has been revised within this policy: A2024​

Revisions From MA11.015z:
07/01/2024This policy has been identified for the HCPCS code update, effective 07/01/2024.

The following HCPCS codes have been added to this policy as Medically Necessary: Q4311, Q4312, Q4314, Q4317, Q4318, Q4319, Q4320, Q4321, Q4322, Q4325, Q4326, Q4327, Q4328, Q4329, Q4330, Q4331, Q4332, Q4333 

The following HCPCS codes have been removed from this policy: Q4210, Q4277​

Revisions From MA11.015y:
04​/01/2024This version of the policy will become effective 04/01/2024​.​

The following HCPCS codes have been added to this policy as Medically Necessary:

A2026, Q4305, Q4306, Q4307, Q4308, Q4309 Q4310

The following HCPCS codes have been removed from this policy: Q4244​

Revisions From MA11.015x:
01​/02/2024This version of the policy will become effective 01/02/2024​.​

The following HCPCS codes have been added to this policy as Medically Necessary: Q4279, Q4287, Q4288, Q4289, Q4290, Q4291, Q4292, Q4293, Q4294, Q4295, Q4296, Q4297, Q4298, Q4299, Q4300, Q4301, Q4302, Q4303, Q4304

The following HCPCS narrative has been revised in this policy: Q4225​

Revisions From MA11.015w:
​01/01/2024

​Effective 01/01/2024 this policy applies to New Jersey Medicare Advantage (MA) lines of business.​
01/01/2024This version of the policy will become effective 01/01/2024.

The following HCPCS code has been deleted from this policy:
  • ​Q4233 ​​Surfactor or NuDyn, per 0.5 cc​​
The Company's coverage position has changed from Medically Necessary to Experimental/Investigational for Q4233 Surfactor or NuDyn, per 0.5 cc​

Revisions to Attachment A listing Skin Substitutes, which are represented by a specific HCPCS code, and their approved indications

  • The following skin substitutes were added to Attachment A of this policy:  Barrera sl or Barrera dl, Biovance tri-layer or biovance 3l, Complete ft, Complete sl, Cygnus dual, Dermabind sl, Epieffect, Esano aaa, Esano ac, Esano aca, Innovaburn or innovamatrix xl, Innovamatrix pd, Kerecis omega3 marigen shield, Miro3d, Neomatrix, Neostim, Orion, Resolve matrix, Surgraft ft, Surgraft xt, Woundplus membrane or e-graft, and Xcell amino matrix.​​
  • The following skin substitutes were removed from Attachment A of this Policy:​ Surfactor and NuDyn
​
Revisions From MA11.015v:
10/01/2023This policy has been identified for the HCPCS code update, effective 10/01/2023​.

The following HCPCS codes have been added to this policy as Medically Necessary: A2022, A2023, A2024, and A2025​

Revisions From MA11.015u:
07/01/2023This policy has been identified for the HCPCS code update, effective 07/01/2023​.

The following HCPCS codes have been added to this policy as Medically Necessary: Q4272, Q4273, Q4274, Q4275, Q4276. Q4277, Q4278, Q4280, Q4281, Q4282, Q4283, Q4284​​

Revisions From MA11.015t:
04/01/2023This policy has been identified for the HCPCS code update, effective 04/01/2023​.

The following HCPCS codes have been added to this policy as Medically Necessary: A2019, A2021, Q4265, Q4266, Q4267, Q4268, Q4269, Q4270, Q4271​

Revisions From MA11.015s:
01/01/2023This version of the policy will become effective 01/01/2023.

The following medical criteria was revised:

The wound has adequate circulation/oxygenation to support tissue growth/wound healing as evidenced by physical examination (e.g., Ankle-Brachial Index (ABI) between 0.60 and 1.4, toe pressure > 30 mm Hg)

The following 01/01/2023 HCPCS codes were added to the policy: Q4236, Q4262, Q4263, Q4264

The following skin substitute was added under HCPCS Code Q4100 in the coding table: Myriad Matrix

The following HCPCS code ​has been deleted effective 01/01/2023: C1849​

Revisions to Attachment A listing Skin Substitutes, which are represented by a specific HCPCS code, and their approved indications

  • The following skin substitutes were added to Attachment A of this policy: Amniobind, Apis, CarePATCH, Celera Dual Layer, Celera Dual Membrane, Cocoon Dual-Layer and Single-Layer Membranes, Dual Layer Impax Membrane, Enverse, Human health factor 10 amniotic patch (HHF10-P), Innovamatrix AC, Innovamatrix FS, Mlg-Complete, Mirragen Advanced Wound Matrix, Myriad Matrix, Omeza Collagen Matrix, Permeaderm B, Permeaderm C, ​Phoenix Wound Matrix, Relese, Restrata, Signature Apatch, Supra SDRM, Suprathel, SurGraft TL, Symphony, Tag, Theragenesis, and XCellistem​.​

Revisions From MA11.015r:
10/01/2022This policy has been identified for the HCPCS code update, effective 10​/01/2022.

The following HCPCS codes have been added to this policy as Medically Necessary: A2014, A2015, A2016, A2018

The following HCPCS narrative has been revised in this policy: Q4128

Revisions From MA11.015q:
07/01/2022This policy has been identified for the HCPCS code update, effective 07​/01/2022.

The following HCPCS codes have been added to this policy as Medically Necessary: Q4259, Q4260, Q4261​

The following HCPCS narrative has been revised in this policy: A2004

Revisions From MA11.015p:
04/01/2022This policy has been identified for the HCPCS code update, effective 04/01/2022.

The following HCPCS codes have been added to this policy as Medically Necessary: ​A2011, A2012, A2013, Q4224, Q4225, Q4256, Q4257, Q4258

​The following code is used to represent skin substitutes that are FDA cleared as a device​, and has been added to this policy: A4100​


Revisions From MA11.015o:
01/01/2022This policy has been identified for the HCPCS code update, effective 01/01/2022.

The following HCPCS codes have been added to this policy as Medically Necessary: ​A2001, A2002, A2003, A2004, A2007, A2008, A2009, A2010, Q4199
____________________________________________________________________

NOTE:​ On 01/04/2022, this policy was updated with the following coding changes effective 01/01/2022.

CMS made a correction and the following HCPCS code was removed from the 01/01/2022 release:​ A2003.

As a result, HCPCS code A2003 was removed from this policy.​​

Revisions From MA11.015n:
12/20/2021This version of the policy will become effective 12/20/2021.

Revisions to Attachment A listing Skin Substitutes, which are represented by a specific HCPCS code, and their approved indications

  • The following skin substitutes were added to Attachment A of this policy: Vendaje, VIM Amniotic Membrane, Zenith Amniotic Membrane
  • The following skin substitute were removed from Attachment A of this policy because they are no longer manufactured or used​: BioNextPATCH, carePATCH​

Revisions From MA11.015m:
10/01/2021This policy has been identified for the HCPCS code update, effective 10/01/2021.

The following HCPCS codes have been added to this policy as Medically Necessary: Q4251, Q4252, Q4253

​The following HCPCS codes have been removed from this policy: Q4228, Q4236

Revisions From MA11.015l:
12/21/2020This version of the policy will become effective 12/21/2020.

NOTABLE REVISIONS TO THE POLICY

Billing Requirements
  • The following skin substitutes were added to the list of skin substitutes in which application codes are not to be reported: Amniotext, Axolotl Ambient, Axolotl Cryo, Cogenex Flowable Amnion, Corplex P, CoreText, Fluid Flow, Fluid GF, NuDyn, Procenta, ProText, and SurFactor.
Coding
  • The following HCPCS codes have been removed from this policy because the products they describe are classified as Bandages/Surgical Dressings, not Skin Substitutes: A6460, A6461
Revisions to Attachment A listing Skin Substitutes, which are represented by a specific HCPCS code, and their approved indications​

  • The following skin substitutes were added to Attachment A of this policy:
    AltiPly, AmnioAMP-MP, AmnioCore, Amnio-Maxx, Amnio-Maxx Lite​, ​Amnion Bio, Axobiomembrane​, Amniorepair, ​Amniotext, Amniotext Patch​, AmnioWrap2​, ​Amniply, ​Artacent Cord, Axolotl Ambient, Axolotl Cryo, Axolotl DualGraft, Axolotl Graft, BellaCell HD, BioNextPATCH, BioWound, BioWound Plus, BioWound XPlus, ​carePATCH, Cellesta Cord, Cogenex Amniotic Membrane, Cogenex Flowable Amnion, ​CoreText, Corplex, Corplex P, Cryo-Cord, Derm-Maxx, DermACELL AWM, DermACELL AWM Porous, Dermacyte, Fluid Flow, Fluid GF, ​​Kerasorb, Membrane Graft, Membrane Wrap, ​Novafix, Novafix DL, NuDyn, Procenta, ProgenaMatrix, ProText, REGUaRD, ​Stravix, Stravix PL, SureDerm Acellular Dermal Matrix, SurFactor, SurgiCORD, SurgiGRAFT-DUAL, SurGraft, Therion, WoundFix, WoundFix Plus, WoundFix XPlus Membrane, XCellerate​

Revisions From MA11.015k:
10/01/2020This policy has been identified for the HCPCS code update, effective 10/01/2020.

The following HCPCS codes have been added to this policy as Medically Necessary: Q4249, Q4250, Q4254, Q4255​

Revisions From MA11.015j:
07/01/2020This policy has been identified for the HCPCS code update, effective 07/01/2020.

The following HCPCS codes have been added to this policy as Medically Necessary: C1849, Q4227, Q4228, Q4229, Q4230, Q4231, Q4232, Q4233, Q4234, Q4235, Q4236, Q4237, Q4238, Q4239, Q4244, Q4245, Q4246, Q4247, Q4248

The following HCPCS narrative has been revised in this policy: Q4176

Revisions From MA11.015i:
10/01/2019This policy has been identified for the HCPCS code update, effective 10/01/2019.

The following HCPCS codes have been added to this policy as Medically Necessary: Q4205, Q4206, Q4208, Q4209, Q4210, Q4211, Q4214, Q4215, Q4216, Q4217, Q4218, Q4219, Q4220, Q4221, Q4222

The following HCPCS narratives have been revised in this policy: Q4122, Q4165, Q4184

Revisions From MA11.015h:
07/29/2019NOTABLE REVISIONS TO THE POLICY

Policy

CHRONIC NON-HEALING WOUNDS

The following criteria has been revised:
    FROM: The wound is clean and free of necrotic debris or exudate
    TO: The wound is clean and free of infection, necrotic debris, or exudate, and without evidence of underlying osteomyelitis

COVERAGE LIMITATIONS

The following criteria have been added to the policy:
  • It is expected that a specific skin substitute will be used for each documented wound, and in compliance with FDA assessments and guidelines for the specific skin substitute.
  • Treatment of any chronic wound will typically last no more than 12 weeks.
  • Greater than 10 applications for the treatment of a single wound within a 12-week period of time is considered not medically necessary.
  • Simultaneous use of more than one skin substitute for the treatment of a single wound within a 12-week period of time is considered not medically necessary. A change in skin substitute within the 12-week treatment period is covered, as long as the 10 application limit per wound is not exceeded.

Billing Requirements
  • The following skin substitutes were added to the list of skin substitutes in which application codes are not to be reported: Artacent AC Powder, Cellesta Flowable Amnion, FlowerFlo (FlowerAmnioFlow), Keroxx Flowable Wound Matrix, Restorgin AFT.
  • The following skin substitutes were removed from the list of skin substitutes in which application codes are not to be reported because these products have been discontinued: Amniogen-A, Amniogen-C, AmnioPro Flow, BioRenew Flow.

Policy Guidelines
  • The definition of a non-healing wound (i.e., "a failed response") has been revised.
  • The following skin substitutes were added to the list of skin substitutes in which there is no Medicare coverage determination:
    Amnio Wound, AmnioArmor, Artacent AC Powder, Cellesta Amniotic Membrane, Cellesta Flowable Amnion, Coll-e-derm, EpiCord, FlowerDerm, FlowerFlo (FlowerAmnioFlow), Geistlich Derma-Gide, Genesis Amniotic Membrane, Keroxx Flowable Wound Matrix, Matrion, NeoPatch, Novachor, PuraPly Antimicrobial XT Wound Matrix, Restorgin AFT, Restorigin Amnion Patch, SkinTE, surgiGRAFT, XWRAP.
  • The following skin substitutes were removed from the list of skin substitutes in which there is no Medicare coverage determination:
    Amniogen-A, Amniogen-C, AmnioPro Flow, Artacent Wound, BioRenew Flow, Miroderm, PalinGen Membrane, PalinGen XPlus Membrane

Revisions to Attachment A
  • The following skin substitutes were added to Attachment A of this policy:
    Amnio Wound, AmnioArmor, AmnioExCel Plus, Artacent AC, Artacent AC Powder, Cellesta Amniotic Membrane, Cellesta Flowable Amnion, Coll-e-derm, FlowerDerm, FlowerFlo (FlowerAmnioFlow), FlowerPatch (FlowerAmnioPatch), Geistlich Derma-Gide, Genesis Amniotic Membrane, GrafixPL Core, GrafixPL Prime, Kerecis Omega3 Wound, Keroxx Flowable Wound Matrix, Matrion, NeoPatch, Neox Cord RT, Novachor, PalinGen ProMatrX ACF, PuraPly Antimicrobial XT Wound Matrix, Restorgin AFT, Restorgin Amnion Patch, Revita, SkinTE, surgiGRAFT, XWRAP.
  • The following skin substitutes were removed from Attachment A because these products have been discontinued:
    Amniogen-45, Amniogen-200, Amniogen-A, Amniogen-C, AmnioPro, AmnioPro Flow, BioRenew, BioRenew Flow.

Revisions From MA11.015g:
01/01/2019The following HCPCS codes have been added to the policy as medically necessary:
Q4183 Q4184 Q4185 Q4186 Q4187 Q4188 Q4189 Q4190 Q4191 Q4192 Q4193 Q4194 Q4195 Q4196 Q4197 Q4198 Q4200 Q4201 Q4202 Q4203 Q4204

The following HCPCS codes have been added to the policy as experimental/investigational:
A6460 A6461

The following code was deleted: Q4131 Q4172

Revisions From MA11.015f:
01/01/2018This policy has been identified for the HCPCS code update effective 01/01/2018.

The following HCPCS codes have been added to this policy: Q4176, Q4177, Q4178, Q4179, Q4180, Q4181

Transcyte has been removed from the list of medically necessary skin substitutes that are to be reported using NOC code Q4100 and is replaced by HCPCS code Q4182.

The following HCPCS narratives have been revised in this policy: Q4132, Q4133, Q4148, Q4156, Q4158, Q4162, Q4163

Revisions From MA11.015e:
12/01/2017POLICY SECTION
    Chronic Non-Healing Wounds
    • Criteria was revised in the policy section regarding Chronic Non-Healing Wounds.
    • Language defining chronic wounds and non-healing wounds was moved from the policy section to the Guidelines section.

    Deep Second-Degree (Partial-Thickness) Burns and Third-Degree (Full-Thickness) Burns
    • Integra Omnigraft Dermal Regeneration Matrix was added as Medically Necessary for burn wounds when medical necessity criteria in the policy are met.
    • Language was removed from the policy section regarding all other uses of the Integra Dermal Regeneration Template.

    Experimental/Investigational
    • AlloPatch HD and Matrix HD were removed from the list of Experimental/Investigational skin substitutes because they are considered Medically Necessary.
    • Alloderm, Allowrap Dry/Allowrap DS, Arthroflex, BioDFence DryFlex, Cymetra, FlexHD Acellular Dermal Matrix, Repriza, Strattice Tissue Matrix, and XCM Biologic Tissue Matrix were removed from the list of Experimental/Investigational skin substitutes because they are used to treat conditions other than burns and chronic, non-healing wounds, which is out of scope for this policy.

    Billing Requirements
    • Under billing requirements, the following skin substitutes were added to the list of skin substitutes in which application codes are not to be reported: AmnioBand Particulate, Amniogen-A, Amniogen-C, AmnioPro Flow, BioRenew Flow, BioSkin Flow, Interfyl, MatriStem MicroMatrix, PalinGen Flow, PalinGen SportFlow, ProMatrX ACF, and WoundEx Flow.

POLICY GUIDELINES SECTION
    • Language defining standard wound therapy was added to the Policy Guidelines section.
    • In the Policy Guidelines Section, the following skin substitutes were added to the list of skin substitutes in which there is no Medicare coverage determination addressing them: AmnioBand Particulate, Amniogen-A, Amniogen-C, AmnioPro Flow, Artacent Wound, BioRenew Flow, BioSkin Flow, Cygnus, Interfyl, Miroderm, PalinGen Flow, PalinGen SportFlow, PalinGen Membrane, PalinGen XPlus Membrane, ProMatrX ACF, TruSkin, WoundEx Flow.
    • In the Policy Guidelines Section, the following skin substitutes were removed from the list of skin substitutes in which there is no Medicare coverage determination addressing them: Alloderm, Allopatch HD, Allowrap DS or Dry, Architect Extracellular Collagen Matrix, Arthroflex, BioDfence Dryflex, Cymetra, Flex HD, Matrix HD, Repriza, Strattice TM, TenSIX Acellular Dermal Matrix, XCM Biologic Tissue Matrix

    Benefit Applications
    • Under Benefit Applications, Alloderm, Allopatch HD, Allowrap Dry/Allowrap DS, Arthroflex, BioDFence DryFlex, Cymetra, FlexHD Acellular Dermal Matrix, Matrix HD, Repriza, Strattice Tissue Matrix, and XCM Biologic Tissue Matrix were removed from the Experimental/Investigational statement.

CODING
    • The following statement was added to ICD-10 Diagnosis Codes: Report the most appropriate diagnosis code in support of medically necessary criteria as listed in the policy.
    • The following HCPCS codes were removed from this policy: Q4112, Q4116, Q4125, Q4130, Q4138, Q4142, Q4143, Q4150
    • HCPCS code Q4128 was moved from Experimental/Investigational to Medically Necessary in the coding table.

CREATION OF ATTACHMENT A
    • Attachment A, which contains a table listing FDA approved/regulated skin substitutes and their approved indications, was created.

Revisions From MA11.015d:
01/01/2017This policy has been identified for the HCPCS code update, effective 01/01/2017.

The following HCPCS codes have been deleted from this policy: C9349, Q4119, Q4120, Q4129

The following HCPCS codes have been added to this policy: Q4166, Q4167, Q4168, Q4169, Q4170, Q4171, Q4172, Q4173, Q4174, Q4175

The following HCPCS narratives have been revised in this policy: Q4105, Q4131

Revisions From MA11.015c:
12/09/2016This policy has been reissued in accordance with the Company's annual review process.
01/01/2016This policy has been identified for the HCPCS code update, effective 01/01/2016.

The following HCPCS codes have been added to this policy: Q4161, Q4162, Q4163, Q4164, Q4165

The following HCPCS narrative has been revised in this policy: Q4153

Revisions From MA11.015b:
07/01/2015The following HCPCS narrative has been revised in this policy:

C9349:

FROM: FortaDerm, and FortaDerm Antimicrobial, any type, per sq cm
TO: PuraPly, and PuraPly Antimicrobial, any type, per sq cm

Revisions From MA11.015a:
06/19/1015This policy was updated to communicate the change in coverage determination for skin substitutes when used in the treatment of burns and chronic non-healing wounds.

Skin substitute products with FDA clearance/approval, when used in the treatment of burns and chronic, non-healing wounds, are considered medically necessary, when provided in accordance with that product's FDA-labeled or cleared indication, and in accordance with that product's individualized application guidelines.

The following changes were made to the coding table:
  • All ICD-9 and ICD-10 Diagnosis Codes were removed from the policy.
  • The following HCPCS codes were added to the policy as Medically Necessary: C9349, Q4141, Q4146, Q4147, Q4149, Q4151, Q4152, Q4153, Q4154, Q4155, Q4156, Q4157, Q4158, Q4159, Q4160.
  • The following HCPCS codes were changed from Experimental/Investigational to Medically Necessary: Q4103, Q4110, Q4111, Q4113, Q4114, Q4115, Q4117, Q4118, Q4119, Q4120, Q4121, Q4122, Q4123, Q4124, Q4126, Q4127, Q4129, Q4131, Q4132, Q4133, Q4134, Q4135, Q4136, Q4137, Q4139, Q4140, Q4145, Q4148.
  • OrCel (Q4100) was changed from Experimental/Investigational to Medically Necessary.
  • The following HCPCS codes were added to the policy as Experimental/Investigational: Q4128, Q4130, Q4142, Q4143, Q4150.

Revisions From MA11.015:
01/01/2015This is a new policy.

10/1/2026
10/1/2026
MA11.015
Medical Policy Bulletin
Medicare Advantage
{"3298": {"Id":3298,"MPAttachmentLetter":"A","Title":"Skin substitutes and their approved indications.","MPPolicyAttachmentInternalSourceId":10498,"PolicyAttachmentPageName":"8b08127d-c6ce-44ba-bba1-73ea2befac20"},}
No